前往化源商城

362-07-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Tubulin beta-2B chain
External ID: CHEMBL820780
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 2002
Volume: 45
Issue: 21
First Page: 4748
Last Page: 4754
DOI: 10.1021/jm020218r

Target ChEMBL ID: CHEMBL2094134
ChEMBL Target Name: Tubulin
ChEMBL Target Type: PROTEIN FAMILY - Target is a group of closely related proteins
Relationship Type: D - Direct protein target assigned
Confidence: Multiple direct protein targets may be assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
6.3IC50=6300nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1266185
Protocol: N/A
Comment: Journal: Nat Chem Biol
Year: 2007
Volume: 3
Issue: 5
First Page: 268
Last Page: 273
DOI: 10.1038/nchembio873
Standard TypeStandard UnitsActivity Comment
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
Inhibition%Not Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_AG_FLUO8_1536_1X%ACT PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as agonists of the human M1 muscarinic receptor (CHRM1; M1). In this assay, CHO-K1 cells stably expressing human M1 are loaded, intracellularly with the calcium indicator dye, Fluo-8, followed by treatment with agonist control or test compounds. As designed, compounds that act as CHRM1 agonists will increase intracellular calcium mobilization, resulting in increased relative fluorescence of the indicator dye and well fluorescence. Compounds are tested in singlicate at a final nominal concentration of 3 uM.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 ug/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 uL of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 uL of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were dispensed to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470-495 nm excitation and 515-575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices). Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay. A ratio for each well was calculated to normalize assay data, according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read.
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent activation was calculated from the median ratio as follows:

%_Activation = ( ( Ratio_Test_Compound - Median_Ratio_Low_Control ) / ( Median_Ratio_High_Control - Median_Ratio_Low_Control ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing DMSO.
High_Control is defined as wells containing Acetylcholine (EC100) and DMSO.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally activating compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent activation of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter for the entire run, i.e. any compound that exhibited greater % activation than the entire screen's cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed primary activation. Negative % activation values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-1, and for inactive compounds 1-0.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50 ug/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250 mM (pH 8.0); (Sigma P8761)
Agonist: Acetylcholine (50 mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Activation at 3 uM
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
-1.07
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:DU-145
External ID: CHEMBL2040531
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: ACS Med. Chem. Lett.
Year: 2012
Volume: 3
Issue: 1
First Page: 5
Last Page: 9
DOI: 10.1021/ml200232c

Target ChEMBL ID: CHEMBL613508
ChEMBL Target Name: DU-145
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
80.5GI50=80500nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:23265 靶标:
External ID: IucA Pilot Assay Tocris Library
Protocol: A solution containing 55.6 mM HEPES pH 7.5, 0.11% Tween 20, 16.7 mM MgCl2, 55.6 mM hydroxylamine, 55.6 microM ATP, 55.6 microM citrate, and 0.28 U/mL IPP was dispensed (45 microL) into clear polystyrene microplates (Corning, Inc.) using a BioTek MicroFlo dispenser.

Next, 40 nL of test compounds (10 mM in DMSO, 8 microM final concentration) were transferred from deep-well blocks to the reaction solution using a stainless-steel pin tool operated by a robotic workstation (JANUS, PerkinElmer, Waltham, MA). The IucA-catalyzed reaction was initiated by adding 5 microL of 3 microM IucA in 25 mM HEPES, 75 mM NaCl, and 0.1 mM TCEP at pH 7.5.

The reactions were allowed to proceed for 30 min at room temperature before being quenched by dispensing (microFill, BioTek) 13 microL of MG developing solution, containing 1.0 mg/mL MG oxalate, 1.5% (w/v) ammonium molybdate, 0.15% (v/v) Tween 20, and 4.7 N sulfuric acid. After allowing the assay color to develop/stabilize for 30 min, the absorbance at 620 nm was measured (EnVision 2103 Multilabel Microplate Reader, PerkinElmer).

Average positive controls from 24 wells with no test compound and average negative controls from 8 wells with no enzyme were calculated. Dynamic range was calculated by difference between Avg Pos Control and Avg Neg Control. Percent inhibition was calculated by the ratio of (Avg. Pos. Ctrl - Sample OD) to Dynamic Range.
Comment: Protein Target is
IucA

EMB09144
574 aa
G057_19877
Klebsiella pneumoniae hvKP1

Active compounds were defined by <80% activity at 8 microM screening concentration.
OD%Activity384ID
0.98497.1319127496888TO1A04
1.004100.68831130342TO1A06
1.06110.646227253868TO1A07
1.023104.066889929465TO1A08
1.025104.422529784838TO1A09
1.032105.667269278644TO1A10
1.019103.355610218718TO1A11
1.059110.468407326181TO1A14
1.049108.690208049315TO1A15
1.044107.801108410883TO1A16
1.047108.334568193942TO1A17
1.054109.579307687748TO1A18
1.137124.338361685733TO1A19
1.109119.359403710509TO1A20
1.089115.803005156778TO1A21
1.097117.22556457827TO1A22
0.98998.0210123881216TO1B03
0.98296.7762728943157TO1B04
0.99298.5544721711813TO1B05
1.016102.822150435659TO1B06
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Homo sapiens
External ID: CHEMBL698906
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 2002
Volume: 45
Issue: 21
First Page: 4748
Last Page: 4754
DOI: 10.1021/jm020218r

Target ChEMBL ID: CHEMBL372
ChEMBL Target Name: Homo sapiens
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.052GI50=52nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Tubulin beta-2B chain
External ID: CHEMBL815870
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 1997
Volume: 40
Issue: 15
First Page: 2323
Last Page: 2334
DOI: 10.1021/jm9700833

Target ChEMBL ID: CHEMBL2094134
ChEMBL Target Name: Tubulin
ChEMBL Target Type: PROTEIN FAMILY - Target is a group of closely related proteins
Relationship Type: D - Direct protein target assigned
Confidence: Multiple direct protein targets may be assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
4.1IC50=4100nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:OVCAR-3
External ID: CHEMBL748123
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 1995
Volume: 38
Issue: 12
First Page: 2041
Last Page: 2049
DOI: 10.1021/jm00012a003

Target ChEMBL ID: CHEMBL614213
ChEMBL Target Name: OVCAR-3
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
12GI50=12000nM
3.5GI50=3500nM
0.028GI50=28nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Tubulin beta-2B chain
External ID: CHEMBL815873
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 1995
Volume: 38
Issue: 12
First Page: 2041
Last Page: 2049
DOI: 10.1021/jm00012a003

Target ChEMBL ID: CHEMBL3394
ChEMBL Target Name: Tubulin beta chain
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
4.9IC50=4900nM
4.8IC50=4800nM
1.1IC50=1100nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:OVCAR-3
External ID: CHEMBL749706
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 1997
Volume: 40
Issue: 15
First Page: 2323
Last Page: 2334
DOI: 10.1021/jm9700833

Target ChEMBL ID: CHEMBL614213
ChEMBL Target Name: OVCAR-3
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.63GI50=630nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_PAM_FLUO8_1536_1X%ACT PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as positive allosteric modulators (PAMs) and increase activity of the human M1 muscarinic receptor (CHRM1; M1) in cells pre-treated with a known agonist. In this assay, CHO-K1 cells stably expressing human M1 are loaded with the Fluo-8 calcium indicator dye, followed by addition of test compounds and subsequent treatment with the activator acetylcholine at a concentration that results in 20% activation (EC20). As designed, compounds that act as CHRM1 PAMs will increase calcium mobilization, resulting in increased intracellular calcium and relative fluorescence of the indicator dye beyond that of the EC20 of acetylcholine. Compounds are tested in singlicate at a final nominal concentration of 3 micromolar.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 degrees C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 micrograms/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 microliters of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 degrees C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 microliters of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 degrees C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were transferred to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470-495 nm excitation and 515-575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices) prior to all wells being treated with an EC20 concentration of acetylcholine. Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay. A ratio for each well was calculated to normalize assay data, according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read and;
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent activation was calculated from the median ratio as follows:

% Activation = ( ( Ratio_Test_Compound - Median_Ratio_Low_Control ) / ( Median_Ratio_High_Control - Median_Ratio_Low_Control ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing Acetylcholine at EC20 and DMSO.
High_Control is defined as wells containing Acetylcholine (EC100) and DMSO.

A mathematical algorithm was used to determine nominally activating compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent activation of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter on an individual plate basis, i.e. any compound that exhibited greater % activation than the plate based cutoff parameter was declared active.

PubChem Activity Outcome and Score:

The inactive compounds of this assay have an activity score range of 0 to 78 and the active compounds have an activity score range of 50 to 100.

The reported PubChem Activity Score has been normalized to 100% observed primary activation. Negative % activation values are reported as activity score zero.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50?g/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250mM (pH 8.0); (Sigma P8761)
Potentiator: Acetylcholine (50mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Activation at 3 uM
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.75
9.74
9.74
9.74
9.74
9.74
9.74
9.74
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Homo sapiens
External ID: CHEMBL696631
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 2002
Volume: 45
Issue: 21
First Page: 4748
Last Page: 4754
DOI: 10.1021/jm020218r

Target ChEMBL ID: CHEMBL372
ChEMBL Target Name: Homo sapiens
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
5.3GI50=5300nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Estrogen receptor beta
External ID: CHEMBL678968
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1995
Volume: 38
Issue: 12
First Page: 2041
Last Page: 2049
DOI: 10.1021/jm00012a003

Target ChEMBL ID: CHEMBL2094114
ChEMBL Target Name: Estrogen receptor
ChEMBL Target Type: PROTEIN FAMILY - Target is a group of closely related proteins
Relationship Type: D - Direct protein target assigned
Confidence: Multiple direct protein targets may be assigned
Standard TypeStandard RelationStandard Value
RBA=0.0225
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: SMAD3201
Protocol: Suspensions of trypsinized HEPG2 CAGA-GFP cells were dispensed into white, tissue culture-treated, solid 1536-well plates at 5uL/well (1000 cells/well final concentration) in DMEM medium supplemented with 1% FBS. Plates were incubated at 37 degrees C for 2 hours, after which 23 nL of compounds or DMSO were delivered to each well using a pin tool. One uL of recombinant TGF-beta in DMEM (1% FBS) was then dispensed (500 pg/mL final concentration), and plates were incubated at 37 degrees C for 18 hours. Two uL of CellTiter Glo (Promega), a luminescence-based viability reagent, was dispensed, followed by a 10 minute room temperature incubation. The plates were then measured on a PerkinElmer ViewLux plate reader for luminescence (clear filter) using a 5 second exposure. The %Activity was determined from the corrected luminescence values. Wells containing media only (no cells) were used to normalize %Activity of identified toxic compounds; media-only wells corresponded to 100%Activity (complete cell-killing), while DMSO-dosed cell controls were used to normalize 0%Activity (no toxicity).

Concentration-response curves were fitted to the signals arising from the resulting luminescence. The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity, and compounds were subsequently categorized based on their curve class. Toxic compounds showed concentration-dependent decreases in luminescence, concordant with a decrease in intracellular ATP concentration (CellTiter Glo's marker of viability), and thus a decrease in the number of viable cells. Inactive (non-toxic) compounds showed no effect on luminescence signal. Active (toxic) compounds showed concentration dependent decrease in luminescence.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description".

2. For all inactive (non-toxic) compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active (toxic) compounds, a score range was given for each curve class type given above. Active (toxic) compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.018 uMActivity at 0.037 uMActivity at 0.074 uMActivity at 0.164 uMActivity at 0.369 uMActivity at 0.461 uMActivity at 0.737 uMActivity at 0.922 uMActivity at 1.840 uMActivity at 2.300 uMActivity at 3.690 uMActivity at 4.610 uMActivity at 9.233 uMActivity at 20.57 uMActivity at 46.10 uMActivity at 92.20 uMCompound QC
Inactive40 0 0 0 00.259610.7694.1255-1.6909-0.74870.2596QC'd by "Chem Div"
Inactive40 0 0 0 0-0.8876-5.2018-3.67070.33032.9155-0.8876QC'd by "Chem Div"
Inactive40 0 0 0 0-4.2306-10.0984-0.7957-0.93222.0609-4.2306QC'd by "Chem Div"
Inactive45.8218-1.6618-3.05539.7773-4.1735.8218QC'd by "Chem Div"
Inactive4-3.265111.605-17.88485.978514.3087-3.2651QC'd by "Chem Div"
Inactive40 0 0 0 0-7.2413.20083.9728-4.51213.9811-7.241QC'd by "Chem Div"
Inactive40 0 0 0 0-9.8078.98690.34840.37287.0197-9.807QC'd by "Chem Div"
Cytotoxic17.782835.5846Partial curve; partial efficacy-4.752.30310.9974-42.6167-7.0321-2.20 0 0 0 0-39.1036-6.2767-6.4175-8.2439-13.6777-39.1036QC'd by "Chem Div"
Cytotoxic3.548140.0619Single point of activity-5.454.95490.8999-40.3659-0.3039-30 0 0 0 12.6367-8.3337.8061-1.7484-40.23322.6367QC'd by "Chem Div"
Inactive40 0 0 0 10.54241.65919.664714.274915.58960.5424QC'd by "Chem Div"
Inactive40 0 0 0 05.9628-8.298-2.31046.1361-3.44285.9628QC'd by "Chem Div"
Inactive40 0 0 0 0-1.0151-4.6247-5.8885-4.492-0.7127-1.0151QC'd by "Chem Div"
Inactive4-0.9022-1.288913.9053-1.0794.3101-0.9022QC'd by "Chem Div"
Inactive40 0 0 0 0-23.5202-1.57517.1469-12.67219.6037-23.5202QC'd by "Chem Div"
Inactive40 0 0 0 1-0.075-0.6173-0.87325.1352.1913-0.075QC'd by "Chem Div"
Cytotoxic35.481333.3813Single point of activity-4.454.95490.4913-37.3813-4-30 0 0 0 0-30.3178-0.6381-23.6633-3.83866.0591-30.3178QC'd by "Chem Div"
Inactive40 0 0 0 0-17.4140.1464-4.8771-5.0687-7.6162-17.414QC'd by "Chem Div"
Inactive4-4.6673-7.1501-3.3264-4.1232-3.249-4.6673QC'd by "Chem Div"
Inactive40 0 0 0 0-17.38786.57262.9374-7.8375-3.1433-17.3878QC'd by "Chem Div"
Inactive40 0 0 0 1-10.2269-7.0609-5.5812-5.82172.0518-10.2269QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Estrogen receptor beta
External ID: CHEMBL678971
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1995
Volume: 38
Issue: 12
First Page: 2041
Last Page: 2049
DOI: 10.1021/jm00012a003

Target ChEMBL ID: CHEMBL2094114
ChEMBL Target Name: Estrogen receptor
ChEMBL Target Type: PROTEIN FAMILY - Target is a group of closely related proteins
Relationship Type: D - Direct protein target assigned
Confidence: Multiple direct protein targets may be assigned
Standard TypeStandard RelationStandard Value
RBA=0.245
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:PC-3
External ID: CHEMBL4407037
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2019
Volume: 178
First Page: 131
Last Page: 140
DOI: 10.1016/j.ejmech.2019.05.067

Target ChEMBL ID: CHEMBL390
ChEMBL Target Name: PC-3
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
Activity=50%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Burnham Center for Chemical Genomics 靶标:cystic fibrosis transmembrane conductance regulator [Homo sapiens]
External ID: SBCCG-A764-CF-PAF-Primary-Assay
Protocol: Assay Materials:
KKLEB-NFkB-GFP cells (Assay Provider)
PAF(Assay Provider)
Fetal Bovine Serum (Hyclone SH30396.03)
Penicillin Streptomycin solution
L-glutamine (100X)
TrypLE (Invitrogen 12563)
DPBS without calcium and magnesium (1X)
Corning culture flasks
Black CellBind 1536-well plates (Corning 3833)
ATPlite (Perkin Elmer 6016739)

I. Cell Suspension
1- Dispense 3 uL/well of cells at 5X10;5 cells/mL to the whole plate (plate cells in 2% FBS assay media).
2- Spin down plates on Eppendorf centrifuge 5810 at 500 rpm for 1 minute.

II. Compound Addition:
3- Transfer test compounds to columns 5-48 and DMSO to columns 1-4 using the Labcyte ECHO 555.
4- Transfer volume of test compound and DMSO is 15nL, making 5uM compound concentration at 0.25% DMSO final.
5-Spin down plates on Vspin at 1000 rpm for 1 minute.
6-Put Kalypsys metal lids on plates, incubate plates at 37 degrees C with 5% CO2 for 2 hours.

III. Reagent Addition
7- Dispense 3 uL/well of serum free assay media to columns 1 and 2.
8- Dispense 3 uL/well of PAF (dilute in serum free assay media) to columns 3-48.
9- Spin down plates without lids on Vspin at 2000 rpm for 2 min
10- Put Kalypsys metal lids on plates, and incubate plates at 37 degrees C with 5% CO2 overnight.

IV. Reading plates:

11-Spin plates upside down with a container at 1000 rpm for 15 sec. Dab them with a tissue to dry them and Read immediately on envision for GFP fluorescence.
12-Dispense 6 uL/well of ATPlite (diluted in DPBS 1:1).
13-Spin down plates on Eppendorf centrifuge 5810 at 2000 rpm for 2 minutes without lids.
14-Incubate plates for 10 min at RT and run Luminescence read on Viewlux.
Comment: Compounds that demonstrated a corrected %Activity of >= 50% at 5 uM concentration are defined as actives in this assay.

The experimental values were normalized by the difference between values from neutral and stimulator control wells in each plate. Then normalized data was corrected to remove systematic plate patterns due to artifacts such as dispensing tip issues etc. Further information about data correction is available at http://www.genedata.com/products/screener.html.

To simplify the distinction between the inactives of the primary screen and of the confirmatory screening stage, the Tiered Activity Scoring System was developed and implemented. Its utilization for the assay is described below.

Activity Scoring
Activity scoring rules were devised to take into consideration compound efficacy, its potential interference with the assay and the screening stage that the data was obtained. Details of the Scoring System will be published elsewhere. Briefly, the outline of the scoring system utilized for the assay is as follows:
1) First tier (0-40 range) is reserved for primary and single-concentration confirmation screening data.
a. If outcome of the primary screen is inactive, then the assigned score is 0
b. If outcome of the primary screen is inconclusive, then the assigned score is 10
c. If outcome of the primary screen is active, then the assigned score is 20
d. If outcome of the single-concentration confirmation screen is inactive, then the assigned score is 21
e. If outcome of the single-concentration confirmation screen is inconclusive, then the assigned score is 25
f. If outcome of the single-concentration confirmation screen is active, then the assigned score is 30.
This scoring system helps track the stage of the testing of a particular SID. For the primary hits which are available for confirmation, their scores will be greater than 20. For those which are not further confirmed, their score will stay under 21.

2) Second tier (41-80 range) is reserved for dose-response confirmation data and is not applicable in this assay

3) Third tier (81-100 range) is reserved for resynthesized true positives and their analogues and is not applicable in this assay
%Activity at 5 uMValueMean LowStd Deviation LowMean High Std Deviation High
17.71388986164067.888625.22080144.63200104.91
-5.52023753164067.888625.22080144.63200104.91
-1.91947331164067.888625.22080144.63200104.91
4.91776516164067.888625.22080144.63200104.91
4.41681435164067.888625.22080144.63200104.91
7.11654104164067.888625.22080144.63200104.91
-16.92220014164067.888625.22080144.63200104.91
5.51825441164067.888625.22080144.63200104.91
-10.22135725164067.888625.22080144.63200104.91
13.11722580164067.888625.22080144.63200104.91
0.11996001164067.888625.22080144.63200104.91
-1.51994666164067.888625.22080144.63200104.91
12.61687553164067.888625.22080144.63200104.91
-12.42138337164067.888625.22080144.63200104.91
1.91864558164067.888625.22080144.63200104.91
14.31574274164067.888625.22080144.63200104.91
20.41414289164067.888625.22080144.63200104.91
67.4531762164067.888625.22080144.63200104.91
3.11778225164067.888625.22080144.63200104.91
53.5823431164067.888625.22080144.63200104.91
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:muscarinic acetylcholine receptor M1 [Homo sapiens]
External ID: CHRM1_ANT_FLUO8_1536_1X%INH PRUN
Protocol: Assay Overview:

The purpose of this assay is to identify compounds that act as antagonists and decrease activity of the human M1 muscarinic receptor (CHRM1; M1) that have been pre-treated with a known agonist, with the end result being a decrease in intracellular calcium. In this assay, CHO-K1 cells stably expressing human M1 are loaded with the Fluo-8 calcium indicator dye. Compounds are added followed by treatment with the activator acetylcholine at a concentration that results in 80% activation (Ec80). As designed, compounds that act as CHRM1 antagonists will decrease calcium mobilization, resulting in decreased relative fluorescence of the indicator dye below that of the Ec80 of acetylcholine. Compounds are tested in singlicate at a final nominal concentration of 3 uM.

Protocol Summary:

The CHO-hM1 cell line was routinely cultured in T-175 sq cm flasks at 37 C and 95% relative humidity (RH). The growth media consisted of Ham's F-12 Nutrient Media (F-12) supplemented with 10% v/v heat-inactivated qualified fetal bovine serum, 20 mM HEPES, 50 ug/mL Geneticin, and 1X antibiotic mix (penicillin and streptomycin).

The day before the assay 3000 cells in 3 uL of growth media were seeded into each well of 1536 well microtiter plates and allowed to incubate at 37 C, 5% CO2, and 95 % RH for 17-24 hours. Next, 2 uL of the fluorogenic Fluo-8 intracellular calcium indicator mixture (prepared according to the manufacturer's protocol) was added to each well. Plates were then incubated for 1 hour at 37 C, 5% CO2, and 95 % RH, followed by 30 minute incubation at room temperature. Then, 15 nL of test compound in DMSO were transferred to appropriate wells. The assay was started by performing a basal read of plate fluorescence (470 - 495 nm excitation and 515 - 575 nm emission) for 5 seconds on the FLIPR Tetra (Molecular Devices) prior to all wells being treated with an EC80 concentration of acetylcholine. Then a real time fluorescence measurement was immediately performed for the remaining 140 seconds of the assay.

Hits for this assay were determined according to the following mathematical expression:

Ratio = I_Max / I_Min

Where:

I_Max represents the maximum measured fluorescence emission intensity over the 140 second read and,
I_Min represents the minimum (basal) measured fluorescence emission intensity before compound was added.

The percent inhibition was calculated from the median ratio as follows:

%_Inhibition = ( 1 - ( Ratio Test_Compound - Median_Ratio_High_Control ) / ( Median_Ratio_Low_Control - Median_Ratio_High_Control ) ) ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Low_Control is defined as wells containing Ec80 of acetylcholine and DMSO.
High_Control is defined as wells containing DMSO.

PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine nominally inhibiting compounds in the primary screen. Two values were calculated for each assay plate: (1) the average percent inhibition of test compound wells and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter for each plate, i.e. any compound that exhibited greater % inhibition than that particular plate's cutoff parameter was declared active.

The reported PubChem Activity Score has been normalized to 100% observed inhibition. Negative % inhibition values are reported as activity score zero.

The PubChem Activity Score range for active compounds is 100-7, and for inactive compounds 80-0.

In this assay not all plates were run in the same batch. This resulted in batch-to-batch variation among the different batches of plates, thereby necessitating the use of a plate-based activity cutoff. For this reason the inactive and active scores overlap.

List of Reagents:

Cell line: Chinese Hamster Ovary (CHO) cells containing hM1 receptor; (Conn Lab)
Calcium sensitive dye: Fluo-8 No Wash Calcium Assay Kit; (AAT Bioquest, part 36316)
Growth media: Ham's F-12; 10% FBS, 20mM HEPES, 50 ug/mL G418
Assay media: Ham's F-12, 10% FBS, 20 mM HEPES
Assay plates: Aurora black/clear 1536well FLIPR plate; (Aurora, part 00019326)
Probenecid: 250mM (pH 8.0); (Sigma P8761)
Potentiator: Acetylcholine (50 mM stock in water); Sigma A9187
Comment: Due to the increasing size of the MLPCN compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, and compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the MLSMR.
Inhibition at 3 uM
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.48
6.47
6.47
6.47
6.47
6.47
6.47
6.47
6.47
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL875731
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 2005
Volume: 48
Issue: 16
First Page: 5243
Last Page: 5256
DOI: 10.1021/jm050066a
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
5.62MGM=5.62uM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:Smad3 [Homo sapiens]
External ID: SMAD3101
Protocol: Suspensions of trypsinized HEPG2 CAGA-GFP cells were dispensed into white, tissue culture-treated, solid 1536-well plates at 5uL/well (1000 cells/well final concentration) in DMEM medium supplemented with 1% FBS. Plates were incubated at 37 degrees C for 2 hours, after which 23 nL of compounds or DMSO were delivered to each well using a pin tool. One uL of recombinant TGF-beta in DMEM (1% FBS) was then dispensed (500 pg/mL final concentration), and plates were incubated at 37 degrees C for 18 hours. The plates were measured on an Acumen eX3 Explorer plate reader for GFP fluorescence (ex488/em500-530). GFP values were calculated by determining the mean GFP fluorescence of individual cells, and compiling these values for each well to determine a total well GFP signal. The %Activity was determined from the corrected fluorescence values. A titration of the known TGF-B inhibitor SB431542 was included to monitor plate performance, while unstimulated HEPG2 (-TGF-B) control wells were used to normalize %Activity of identified inhibitors; unstimulated wells corresponded to 100%Activity (full inhibition), while stimulated cell controls (+DMSO) were used to normalize 0%Activity (no inhibition).

Concentration-response curves were fitted to the signals arising from the resulting fluorescence. The concentration-effect curves were then classified based on curve quality (r2), response magnitude and degree of measured activity, and compounds were subsequently categorized based on their curve class. Active inhibitors showed concentration-dependent decreases in GFP fluorescence, concordant with a decrease in TGF-B/SMAD3-driven GFP expression. Inactive compounds showed no effect on fluorescence signal.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.018 uMActivity at 0.037 uMActivity at 0.074 uMActivity at 0.164 uMActivity at 0.369 uMActivity at 0.461 uMActivity at 0.737 uMActivity at 0.922 uMActivity at 1.840 uMActivity at 2.300 uMActivity at 3.690 uMActivity at 4.610 uMActivity at 9.231 uMActivity at 20.57 uMActivity at 46.10 uMActivity at 92.20 uMCompound QC
Inactive40 0 0 0 027.05699.939810.15150.16715.572127.0569QC'd by "Asinex Ltd."
Inactive40 0 0 0 1-4.9362-9.41412.0824-11.0493-7.696-4.9362QC'd by "Asinex Ltd."
Inactive40 0 0 0 15.95954.342-1.5624-2.6449-8.95385.9595QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-19.7473-1.4487.5701-38.1554-17.3097-19.7473QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-1.2351-5.5487-5.0573-16.62112.7653-1.2351QC'd by "Asinex Ltd."
Inactive40 0 0 0 07.1959-7.76824.48993.399213.37077.1959QC'd by "Asinex Ltd."
Inactive40 0 0 0 18.983315.3354.25354.1946-14.32368.9833QC'd by "Asinex Ltd."
Inactive40 0 0 0 07.9022-10.517413.4936-10.46867.23237.9022QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-11.834712.2839-2.7256-19.2666-5.8034-11.8347QC'd by "Asinex Ltd."
Inhibitor35.4813106.2444Single point of activity-4.454.44950.9934-109.7251-3.4808-30 0 0 0 0-84.6645-7.4849-2.0755-4.81140.1432-84.6645QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-3.6-2.07174.941415.4055-0.2463-3.6QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.7641028.345612.16980.90780.7641QC'd by "Asinex Ltd."
Inactive40 0 0 0 1-3.7338-9.95590.39868.925512.5033-3.7338QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-1.77973.8831.182-4.1851.7497-1.7797QC'd by "Asinex Ltd."
Inhibitor15.848938.9608Single point of activity-4.83.67720.9889-35.46083.5-30 0 0 0 0-32.8842.06775.8192.7318-1.3119-32.884QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-3.7978.4821-2.183612.765.4907-3.797QC'd by "Asinex Ltd."
Inactive40 0 0 0 0-18.74991.02723.81520.51991.7606-18.7499QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.46409.4101-6.52060.90670.464QC'd by "Asinex Ltd."
Inactive40 0 0 0 00.23719.7122-4.6112-6.6419-3.28890.2371QC'd by "Asinex Ltd."
Inactive40 0 0 0 13.67994.89241.7621-1.6686-4.49453.6799QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: ERR513
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-8.61372.09370.7210-9.347240 0 0 0 0 0 0 0-1.1981-7.7893-1.3061-0.91362.7218-2.44492.34910.5984-1.1981QC'd by EnamineInactive0004-2.1799-5.7621-6.6695
Inactive0-5.76374.95490.7632-7.8669040 0 0 0 0 0 0 0-9.70720.11940.8287-2.1801-1.25493.4297-9.8891-4.5089-9.7072QC'd by EnamineInactive0-4.21373.24750.7579-22.3272-240 0 0 0 0 0 0 0-18.1894-7.6164-4.6343
Cytotoxic48.557732.580620Single point of activity-4.31373.29750.9389-34.0806-1.5-30 0 0 0 0 0 0 0-30.48392.00771.2353-4.12-5.6743-2.5921-0.0827-2.7826-30.4839QC'd by EnamineInactive0-4.46372.90230.9774-26.7175-0.540 0 0 0 0 0 0 0-25.1812-1.37171.1119
Inactive0004-4.0244-1.58150.55321.86960.2877-1.0948-0.97181.3168-4.0244QC'd by EnamineInactive00042.6212-1.36331.1082
Inactive0-4.313710.6075-12.9835-1.540 0 0 0 0 0 0 0-9.1529-6.26020.8875-0.2672-1.0757-1.1078-3.3998-4.2513-9.1529QC'd by SIGMAInactive0-4.16374.44950.8449-13.8135-140 0 0 0 0 0 0 0-11.0946-2.2814-1.8218
Inactive0004-2.2635-3.2218-1.5002-3.2094-6.5467-6.9838-9.2586-2.3579-2.2635QC'd by SIGMAInactive0004-2.1934-6.1949-2.9926
Inactive0004-3.6053-10.98-3.1918-5.1884-6.2628-0.9809-3.7687-3.2149-3.6053QC'd by SIGMAInactive0004-2.2311-5.3121.6461
Cytotoxic48.557749.883420Single point of activity-4.31373.29750.9731-52.7952-2.9118-30 0 0 0 0 0 0 0-47.5721-5.7276-1.70880.07121.5459-4.3172-5.7565-4.7314-47.5721QC'd by SIGMACytotoxic68.589655.54720Single point of activity-4.16373.990.9932-57.6622-2.1152-30 0 0 0 0 0 0 0-44.4411-3.0449-2.577
Inactive0-6.36370.20.60998-9.656340 0 0 0 0 0 0 05.2888-8.0469-2.15330.5824-6.7160.56390.89561.59855.2888QC'd by SIGMAInactive0-5.26371.22210.9111-12.426240 0 0 0 0 0 0 15.0335-0.8992.8828
Inactive0-4.16374.44950.8402-12.6467040 0 0 0 0 0 0 0-10.1223-1.34671.9663-1.54012.2503-0.6504-1.39571.3844-10.1223QC'd by SIGMAInactive0004-5.9601-4.8718-1.2894
Inactive0-7.06374.95490.7513-8.96612.540 0 0 0 0 0 0 0-15.38840.7062.90453.3353-8.2144-8.9894-9.0163-3.1514-15.3884QC'd by SIGMAInactive0-4.36373.62720.923-19.77080.540 0 0 0 0 0 0 0-18.5592.3106-3.7006
Cytotoxic43.277175.632420Single point of activity-4.36373.29750.9904-76.4078-0.7754-30 0 0 0 0 0 0 0-70.38471.99022.3693-0.9536-1.7116-0.7698-5.276-6.3803-70.3847QC'd by SIGMACytotoxic48.557782.719420Single point of activity-4.31373.29750.9843-85.6388-2.9194-30 0 0 0 0 0 0 0-76.6203-7.7845-4.8132
Inactive0-4.41370.70.7291-12.603140 0 0 0 0 0 0 0-8.83580.5447-0.27422.49020.87441.9273-4.8205-1.4703-8.8358QC'd by SIGMAInactive0004-3.8112-0.6122-0.8775
Inactive0004-4.7292-2.4847-4.1876-6.48671.0395-0.71620.0299-0.793-4.7292QC'd by SIGMAInactive00042.63140.3943-1.3136
Inactive0-5.81371.64360.80470.5-6.497440 0 0 0 0 0 0 0-0.4266-9.1645-5.8022-3.6937-7.1147-4.6312-0.94771.1703-0.4266QC'd by SIGMAInactive0-4.31374.50450.829513.5-1.965340 0 0 0 0 0 0 012.7252-3.68221.1451
Cytotoxic24.336549.095240Partial curve; partial efficacy-4.61374.50450.9503-50.0798-0.9846-2.20 0 0 0 0 0 0 0-50.0782-0.0272.3579-4.7322-0.13674.7681-8.001-12.0828-50.0782QC'd by SIGMACytotoxic34.376251.39520Partial curve; partial efficacy-4.46371.66040.9408-52.4652-1.0701-2.20 0 0 0 0 0 0 0-46.02210.25280.4999
Inactive0-5.86374.95490.5635-7.1429-140 0 0 0 0 0 0 11.7155-3.0936-3.86271.08310.1892-0.7274-10.5357-4.05151.7155QC'd by LightBiologicalsInactive00041.3344-8.4864-3.5514
Inactive0-8.01374.95490.8219-1.5-15.383740 0 0 0 0 0 0 0-0.1642-15.3198-14.49810.2013-6.9242.4229-4.18230-0.1642QC'd by SIGMAInactive0-5.01374.95490.41315-2.544240 0 0 0 0 0 0 03.88070.31652.8847
Inactive0-7.96374.95490.6746-2.3322740 0 0 0 0 0 0 17.57815.96367.5271-8.1935-0.710.9919-1.6782-0.86047.5781QC'd by SIGMAInactive0-6.11372.72020.84876-3.067540 0 0 0 0 0 0 06.1795-3.1652-6.3062
Cytotoxic43.277130.71920Partial curve; partial efficacy; poor fit-4.36371.46410.9032-33.219-2.5-2.40 0 0 0 0 0 0 0-27.6825-1.9081-4.6287-2.873-0.37610.9727-8.0988-6.6948-27.6825QC'd by SIGMAInactive0-4.76371.88510.9867-25.4518-0.540 0 0 0 0 0 0 0-24.5432-1.7780.5931
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR845
Protocol: Tox21 Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-6.71373.990.74483.5-3.097940 0 0 0 0 0 0 1-4.53010.5359-3.9754-6.3316-1.5343.70283.02253.9166-4.5301QC'd by EnamineInactive0-4.36374.50450.860920.5-2.001440 0 0 0 0 0 0 019.79981.4656-7.5012
Inhibitor38.570835.180610Partial curve; partial efficacy; poor fit-4.41370.30.5495-40.7918-5.6112-2.40 0 0 0 0 0 0 0-30.6598-14.2189-5.7598-1.3427-19.1905-11.1974-18.7235-15.3163-30.6598QC'd by EnamineInactive0-8.76374.95490.5011-5.7381240 0 0 0 0 0 0 0-4.77690.9052-7.1733
Inhibitor43.277177.03210Single point of activity-4.36373.29750.9971-78.3429-1.3109-30 0 0 0 0 0 0 0-72.2295-0.848-0.118-4.2082-0.6518-1.8942-0.08-5.3518-72.2295QC'd by EnamineInhibitor43.277163.648410Single point of activity-4.36372.95230.9946-65.7144-2.0659-30 0 0 0 0 0 0 0-59.6321-2.31811.0274
Inactive0-4.61374.0950.7785-11.2649040 0 0 0 0 0 0 0-11.05412.37760.40940.2158-4.58290.01091.9949-2.9254-11.0541QC'd by EnamineInactive0-4.41373.92950.7033-11.88-140 0 0 0 0 0 0 0-11.56670.6312.2683
Inhibitor13.685430.707521Partial curve; partial efficacy-4.86371.3310.9362-34.9705-4.2631-2.20 0 0 0 0 0 0 0-32.0588-3.9769-3.3008-9.2624-0.6359-6.9717-5.8106-24.2995-32.0588QC'd by SIGMAInhibitor19.331244.710720Partial curve; partial efficacy-4.71374.95490.9424-44.06730.6434-2.20 0 0 0 0 0 0 0-43.91873.3929-7.8909
Inactive0-4.61370.50.86281.139-21.207340 0 0 0 0 0 0 0-4.0509-23.9228-19.6932-21.9663-17.0189-16.3805-16.3485-13.4943-4.0509QC'd by SIGMAInactive0-4.56370.60.86232.9723-21.743540 0 0 0 0 0 0 0-2.5231-21.0888-19.8358
Inactive0-4.66374.0950.7922-16.0186740 0 0 0 0 0 0 0-15.43222.495111.00468.413812.5339-0.02468.6463-1.6168-15.4322QC'd by SIGMAInactive0-4.16374.95490.6395-12.122540 0 0 0 0 0 0 0-8.851710.91192.0118
Inhibitor43.277176.013310Single point of activity-4.36373.29750.9556-72.62463.3888-30 0 0 0 0 0 0 0-67.00170.43212.27294.102815.2231-2.70330.1771-0.4468-67.0017QC'd by SIGMAInhibitor68.589678.061510Single point of activity-4.16374.95490.8832-73.18654.8751-30 0 0 0 0 0 0 0-58.3846-2.614-4.3734
Activator1.219732.68440Complete curve; partial efficacy; poor fit-5.91370.80.948130.5-2.18441.40 0 0 0 0 0 0 029.0103-1.64831.5958-4.32031.836314.835216.647829.69429.0103QC'd by SIGMAActivator48.557744.5940Single point of activity-4.313710.538947.78773.193730 0 0 0 0 0 0 038.027214.7051.0969
Inactive0-4.61374.0950.9713-21.2654-1.540 0 0 0 0 0 0 0-21.0545-2.7301-0.41341.0029-2.2409-1.0812-2.1276-6.3156-21.0545QC'd by SIGMAInactive0-4.41373.990.8429-24.48221.540 0 0 0 0 0 0 0-23.7352-0.6662-2.5056
Activator17.2289133.59920Partial curve; high efficacy-4.76371.55790.9975127.2961-6.30312.10 0 0 0 0 0 0 0117.8667-8.9515-6.7202-3.1268-8.6465-1.68023.809264.311117.8667QC'd by SIGMAActivator21.6899164.62480Partial curve; high efficacy-4.66371.24750.9927156.6074-8.01742.10 0 0 0 0 0 0 0133.1695-7.9286-14.0417
Inhibitor68.589698.74510Single point of activity-4.16374.95490.931-122.9328-24.1879-30 0 0 0 0 0 0 0-104.5347-33.7189-31.4897-29.5277-32.0771-19.6494-24.4139-12.4858-104.5347QC'd by SIGMAInhibitor68.589665.97810Single point of activity-4.16374.44950.9656-93.0438-27.0659-30 0 0 0 0 0 0 0-79.0031-29.1044-30.014
Inactive0-4.11374.95490.6653-23.47291.540 0 0 0 0 0 0 0-16.22742.7934.6828-5.1704-5.88253.40514.4085.1222-16.2274QC'd by SIGMAInactive0004-8.3878-2.7507-9.7834
Inactive0-6.96374.50450.52725-3.781740 0 0 0 0 0 0 012.2006-2.9898-3.919-4.81813.02829.0156-2.12881.783312.2006QC'd by SIGMAInactive0-4.61374.95490.8110.5-1.339640 0 0 0 0 0 0 010.67871.3266-2.2209
Inactive0-4.81370.50.790222-1.879740 0 0 0 0 0 0 016.0881-1.9337-0.9491-0.2665-4.06648.70261.96710.79316.0881QC'd by SIGMAInactive0-4.81371.78850.535915.5-0.482940 0 0 0 0 0 0 014.811-5.402411.5478
Activator5.448365.90960Complete curve; high efficacy-5.26373.51170.992865.1288-0.78081.10 0 0 0 0 0 0 064.12783.4298-0.9076-4.3967-2.59521.436710.934765.698664.1278QC'd by SIGMAActivator8.6349121.11690Partial curve; high efficacy-5.06371.17050.9968115.9495-5.16742.10 0 0 0 0 0 0 0108.5669-5.4351-5.5745
Inactive0-5.71374.95490.595-8.7497040 0 0 0 0 0 0 15.4059-2.6152-3.8122-2.09634.4994.406-9.7914-7.14735.4059QC'd by LightBiologicalsInactive0-4.11374.95490.3408-10.3215040 0 0 0 0 0 0 0-7.3513-4.35072.8856
Inactive0-7.31371.22210.9525-1.4634-23.351240 0 0 0 0 0 0 1-12.6292-20.3271-25.7094-13.6954-6.9291-1.6842-1.5865-0.8028-12.6292QC'd by SIGMAInactive0-6.96372.40640.4996-15.2703040 0 0 0 0 0 0 0-27.72521.4691-2.4748
Activator5.448383.66690Complete curve; high efficacy; poor fit-5.263710.969688.03014.36321.31 0 0 0 0 0 0 082.872636.415612.07881.2155-2.961220.571436.413270.139882.8726QC'd by SIGMAActivator5.4483159.39970Partial curve; high efficacy-5.26370.50.9946149.0275-10.37222.10 0 0 0 0 0 0 0117.16-5.2091-4.8857
Inhibitor68.589652.742510Single point of activity-4.16374.95490.7907-52.540.2025-30 0 0 0 0 0 0 0-42.826-0.156510.14883.0709-2.1032-5.5467-13.87819.2268-42.826QC'd by SIGMAInhibitor68.589648.042810Single point of activity-4.16374.95490.7805-49.2366-1.1938-30 0 0 0 0 0 0 0-40.11641.4546-2.3883
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PGC981
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 17.5 hours. 1 ul/well of CellTiter-Fluor reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at 37 C/5% CO2, the fluorescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-4.86371.47810.785.5-8.060740 0 0 0 0 0 0 04.915-11.7172-10.2261-5.6747-3.2162-8.4895-6.42940.12124.915QC'd by EnamineInactive0-4.71374.95490.71496.5-4.107540 0 0 0 0 0 0 06.3707-4.6171-5.2048
Inactive0-6.66374.95490.6015-3.7977240 0 0 0 0 0 0 0-5.28490.7910.92684.1721.3686-5.48181.3153-6.0814-5.2849QC'd by EnamineInactive0-5.81374.95490.3563-3.9449240 0 0 0 0 0 0 0-7.65024.16730.1723
Cytotoxic0.769679.126986Complete curve; high efficacy-6.11372.40640.989-80.2129-1.086-1.10 0 0 0 0 0 0 0-74.1102-5.396-2.9033-0.44662.7921-36.8956-82.6325-83.0675-74.1102QC'd by EnamineCytotoxic0.685977.815120Complete curve; high efficacy; poor fit-6.16372.40640.9961-79.552-1.7369-1.31 0 0 0 0 0 0 0-75.8034-72.1781-1.7358
Inactive0004-3.6673-6.0811-7.2954-2.9298-5.4835-6.4501-0.8482-0.7681-3.6673QC'd by EnamineInactive00041.9261-2.3973-1.7209
Inactive00043.10533.4072-1.20312.5309-0.51780.13742.52470.33163.1053QC'd by SIGMAInactive00040.58950.0467-1.1307
Inactive0-8.81374.95490.3082-4.4311740 0 0 0 0 0 0 0-0.12874.6299-9.52591.88571.5028-8.8402-7.8944-7.173-0.1287QC'd by SIGMAInactive0-7.21374.95490.6151-5.42113.540 0 0 0 0 0 0 13.27414.48891.0958
Inactive0-4.11374.95490.5878-11.9248-140 0 0 0 0 0 0 0-8.6874-2.6017-2.1396-4.8238-0.7809-0.22621.32562.5681-8.6874QC'd by SIGMAInactive0004-3.0350.9522-1.0902
Cytotoxic24.336546.215220Partial curve; partial efficacy-4.61374.0950.8819-45.84720.3681-2.20 0 0 0 0 0 0 0-45.43845.881-8.1203-9.15891.98714.56915.5262-10.7271-45.4384QC'd by SIGMACytotoxic34.376235.963320Partial curve; partial efficacy; poor fit-4.46371.10.6483-38.4633-2.5-2.40 0 0 0 0 0 0 0-30.38613.9144-10.9322
Inactive0-6.71373.990.8426-7.88744.540 0 0 0 0 0 0 0-2.89953.23475.85414.84131.1609-11.9895-9.9614-6.4748-2.8995QC'd by SIGMAInactive0-6.21374.95490.3993-9.8085-140 0 0 0 0 0 0 1-4.23611.05812.2314
Inactive0004-8.8762-5.923-4.3846-2.7844-3.0174-1.57820.44671.6153-8.8762QC'd by SIGMAInactive0004-2.6033-0.7522-0.3781
Cytotoxic13.685431.192220Partial curve; partial efficacy; poor fit-4.86374.0950.987-28.69222.5-2.40 0 0 0 0 0 0 0-29.32691.0510.82913.02485.19882.44540.8952-21.0544-29.3269QC'd by SIGMACytotoxic30.637939.175420Single point of activity-4.51372.63840.9942-36.67542.5-30 0 0 0 0 0 0 0-33.8452.13522.347
Cytotoxic38.570879.766740Partial curve; high efficacy-4.41372.63840.9853-84.0115-4.2449-2.10 0 0 0 0 0 0 0-76.5239-2.4554-4.41340.9249-10.1622-3.8808-5.616-14.7247-76.5239QC'd by SIGMACytotoxic54.482785.061720Single point of activity-4.26373.24750.9911-91.6046-6.5429-30 0 0 0 0 0 0 0-78.4884-7.7514-8.9605
Cytotoxic19.331237.87620Partial curve; partial efficacy-4.71371.62590.9556-35.95541.9206-2.20 0 0 0 0 0 0 0-33.29621.1258-0.21948.2922-0.93250.73450.067-16.4636-33.2962QC'd by SIGMACytotoxic24.336537.729420Single point of activity-4.61374.95490.9857-38.7294-1-30 0 0 0 0 0 0 0-38.4602-3.9414-2.1898
Inactive0004-2.46990.42311.17392.4494-2.3903-5.8621-2.75422.1121-2.4699QC'd by SIGMAInactive0004-2.214-1.4625-2.7485
Inactive0-4.66374.0950.741112.5-2.679940 0 0 0 0 0 0 012.3306-2.456-4.37830.7114-1.00270.4255-9.31662.996712.3306QC'd by SIGMAInactive0-4.16374.95490.944819.50.267340 0 0 0 0 0 0 015.7501-0.36041.1005
Cytotoxic24.336530.069120Single point of activity-4.61374.0950.9268-30.5691-0.5-30 0 0 0 0 0 0 0-30.4742-6.1565-0.15064.9067-0.89490.097-0.2413-8.1828-30.4742QC'd by SIGMACytotoxic30.637941.734320Single point of activity-4.51373.29750.9593-36.23435.5-30 0 0 0 0 0 0 0-33.40166.88037.6192
Inactive0-5.86370.40.90196.5-8.152440 0 0 0 0 0 0 04.1776-6.9275-6.6426-8.0437-2.1876-0.6978-1.40723.42914.1776QC'd by LightBiologicalsInactive00046.6773-1.88140.4883
Inactive0-4.61374.50450.9231100.077740 0 0 0 0 0 0 010.0385-0.48612.253-0.50310.15970.9668-0.76862.389210.0385QC'd by SIGMAInactive00047.4959-0.5175-0.4627
Inconclusive0.153632.691210Partial curve; partial efficacy; poor fit-6.81370.20.930116-16.69122.40 0 0 0 0 0 0 011.0017-10.576-3.6335-2.6864-0.78383.31442.74056.346611.0017QC'd by SIGMAInactive0-5.01371.75290.63996.5-1.856440 0 0 0 0 0 0 06.2964-1.41730.4366
Cytotoxic48.557732.238220Partial curve; partial efficacy; poor fit-4.31371.10.9013-36.0152-3.7769-2.40 0 0 0 0 0 0 0-26.6793-0.5468-5.0549-6.9535-0.2308-5.7352-8.0532-10.5038-26.6793QC'd by SIGMAInactive0-4.61371.46410.9003-22.7063-2.914740 0 0 0 0 0 0 0-20.1719-4.0675-2.6739
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC428
Protocol: Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive00042.40140.97590.30781.8904-1.32141.1138-1.6886-2.57882.4014QC'd by EnamineInactive00042.2787-0.9694-3.8908
Inactive0004-2.9424-0.1831-2.1441-0.81230.7356-2.795-3.3133-0.3073-2.9424QC'd by EnamineInactive00041.5663-0.9898-2.1656
Inhibitor1.933130.25050Complete curve; partial efficacy-5.71374.95490.9884-32.7505-2.5-1.20 0 0 0 0 0 0 0-32.7088-2.9131-4.6477-3.9229-1.60220.1764-32.5182-31.28-32.7088QC'd by EnamineInhibitor2.16935.34080Complete curve; partial efficacy; poor fit-5.66374.95490.9534-35.28250.0583-1.41 0 0 0 0 0 0 0-36.4368-31.3574-4.1999
Inactive00044.2421-5.00691.1218-0.01471.4143-0.7153-1.8654-1.08794.2421QC'd by EnamineInactive0004-2.4793-2.9079-3.184
Inactive0-4.21373.990.5455-9.5512040 0 0 0 0 0 0 0-7.9593-4.54884.51660.2512-0.7312-1.48191.47-0.0426-7.9593QC'd by SIGMAInactive0004-11.2315-5.6697-2.8914
Inactive0004-4.1758-2.8245-1.44510.5422-0.3307-1.02441.9480.1256-4.1758QC'd by SIGMAInactive00041.6001-3.85641.804
Inactive00044.3768-4.084-2.0739-1.1987-0.2477-0.4857-0.73983.08794.3768QC'd by SIGMAInactive00043.4197-0.1470.119
Inactive0-4.41374.0450.787-9.44140 0 0 0 0 0 0 0-9.1167-0.88074.7479-0.5740.36761.5356-0.56610.5529-9.1167QC'd by SIGMAInactive0-4.16374.95490.9155-18.8168-0.540 0 0 0 0 0 0 0-15.264-3.64431.0791
Inactive00044.56840.73691.2152-0.4642-5.3740.7893-5.2966-0.6674.5684QC'd by SIGMAInactive00043.07711.5072-1.0121
Inactive00045.87980.9788-0.8043-0.16830.5835-0.00870.8357-0.43085.8798QC'd by SIGMAInactive00043.0034.6097-0.2019
Inactive0-4.71370.9310.966716-12.66240 0 0 0 0 0 0 011.1718-11.0163-13.0889-15.135-12.7909-8.7096-8.71320.854911.1718QC'd by SIGMAInactive0-4.66374.0950.96819-8.276140 0 0 0 0 0 0 018.8245-9.1995-8.5885
Inactive0-4.16374.95490.9451-31.7539-2.540 0 0 0 0 0 0 0-26.4616-3.7295-5.2291-3.0969-2.288-3.5247-2.32081.7484-26.4616QC'd by SIGMAInactive0-4.16374.95490.9334-30.6082-2.540 0 0 0 0 0 0 0-25.5069-2.7103-5.3426
Inactive0-4.71374.95490.9407-8.8985040 0 0 0 0 0 0 0-9.08210.3128-1.43780.2924-0.419201.586-4.053-9.0821QC'd by SIGMAInactive0-4.51370.80.6738-13.3555140 0 0 0 0 0 0 0-9.46290.6379-2.0412
Inactive0-8.41370.70.5837-1.07391040 0 0 0 0 0 0 00.29827.47482.23922.15450.68180.246-6.31161.35580.2982QC'd by SIGMAInactive0-6.91374.95490.486-0.784640 0 0 0 0 0 0 00.21723.73181.5014
Inactive0004-2.40140.9093-2.3514-1.26-1.532-1.0946-1.4276-1.3037-2.4014QC'd by SIGMAInactive0004-0.9775-6.6823-0.2967
Activator12.197242.828241Complete curve; partial efficacy-4.91372.95230.987642.7435-0.08481.20 0 0 0 0 0 0 042.6198-2.2542-2.3630.4008-0.30113.44693.268732.944442.6198QC'd by SIGMAActivator15.355343.419221Partial curve; partial efficacy-4.81371.46410.904646.68233.26312.20 0 0 0 0 0 0 043.806214.88091.3724
Inactive00041.3627-0.0701-2.08231.36830.09830.2791.0733-2.83051.3627QC'd by LightBiologicalsInactive0004-0.91481.1123-2.0113
Inactive0-4.61374.0950.936610-2.575240 0 0 0 0 0 0 09.8552-1.1769-2.1967-4.1352-1.5482-4.2293-3.65290.53249.8552QC'd by SIGMAInactive0-4.16374.95490.901717.5-2.621540 0 0 0 0 0 0 013.8866-3.2503-5.5179
Activator7.695944.941241Complete curve; partial efficacy-5.11371.75290.977743.3726-1.56861.20 0 0 0 0 0 0 042.7055-6.7239-3.17491.0732-2.18933.30557.112735.965142.7055QC'd by SIGMAActivator30.637938.378610Partial curve; partial efficacy; poor fit-4.51370.90.890248.3786102.41 1 1 0 0 0 0 038.606523.46220.9144
Inactive0-5.81371.55790.9841-8.5398140 0 0 0 0 0 0 11.1671.751.36320.05350.9714-1.3806-6.7289-8.36651.167QC'd by SIGMAInactive0-5.51372.72020.8571-9.4462040 0 0 0 0 0 0 12.69632.31221.1111
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: ERR136
Protocol: Assay Protocol Summary:

The ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-4.51374.95490.98419.5-3.038640 0 0 0 0 0 0 019.3676-2.3612-2.8082-5.4488-2.2489-2.9112-3.4175-1.559219.3676QC'd by EnamineInactive0004-5.35172.0093-6.4777
Inhibitor48.557736.21060Partial curve; partial efficacy; poor fit-4.31370.90.8071-45.4474-9.2368-2.40 0 0 0 0 0 0 0-34.4298-9.7122-4.364-11.671-16.6813-9.6787-15.4098-16.2365-34.4298QC'd by EnamineInactive0004-11.0366-0.9734-7.3298
Inhibitor43.277183.00920Single point of activity-4.36373.29750.9949-84.0538-1.0446-30 0 0 0 0 0 0 0-77.6923-3.87922.7538-2.3693-0.5727-1.6659-0.0681-5.2567-77.6923QC'd by EnamineInhibitor43.277179.45370Single point of activity-4.36372.95230.9963-81.306-1.8523-30 0 0 0 0 0 0 0-73.3378-0.46270.1851
Inactive0-4.46373.1320.7667-13.4494-140 0 0 0 0 0 0 0-12.8745-0.32052.0373-3.4545-4.74620.00971.7226-2.7713-12.8745QC'd by EnamineInactive0-4.31373.19250.8101-17.6246-240 0 0 0 0 0 0 0-15.9372-5.0774-4.5471
Inhibitor19.331245.63620Partial curve; partial efficacy-4.71374.95490.9167-45.62720.009-2.20 0 0 0 0 0 0 0-45.72563.2263-6.99944.18433.6048-8.45733.4843-19.3083-45.7256QC'd by SIGMAInhibitor21.689948.50050Partial curve; partial efficacy-4.66374.0950.955-49.3184-0.8179-2.20 0 0 0 0 0 0 0-48.9059-6.2148-3.7555
Inactive0-4.16371.1110.75881.2662-20.645940 0 0 0 0 0 0 0-7.6949-23.8716-19.2362-23.8279-16.4076-18.7298-19.3953-17.0738-7.6949QC'd by SIGMAInactive0-4.16371.53860.83570.58-19.195640 0 0 0 0 0 0 0-7.0166-20.3188-16.6054
Inactive0-4.66374.0950.806-16.89936.540 0 0 0 0 0 0 0-16.999410.73521.88666.048412.4092-0.01887.5808-1.5316-16.9994QC'd by SIGMAInactive0-4.16374.95490.883-20.90586.540 0 0 0 0 0 0 0-15.75492.18169.7822
Inhibitor43.277177.27130Single point of activity-4.36374.0950.9569-75.45791.8134-30 0 0 0 0 0 0 0-72.17882.6525-2.2372-1.501514.6872-2.40990.1529-0.4232-72.1788QC'd by SIGMAInhibitor68.589681.50290Single point of activity-4.16374.95490.9901-81.48520.0177-30 0 0 0 0 0 0 0-66.2581-2.2615-3.7766
Activator4.85583010Complete curve; partial efficacy; poor fit-5.31370.70.85413441.40 0 0 0 0 0 0 029.44141.61752.942113.13381.613413.135714.4628.542729.4414QC'd by SIGMAActivator34.376255.960710Partial curve; partial efficacy; poor fit-4.46370.60.793556.35420.39352.40 0 0 0 0 0 0 042.9205-1.42611.3781
Inhibitor68.589634.50210Partial curve; partial efficacy; poor fit-4.16374.95490.973-35.5021-1-2.40 0 0 0 0 0 0 0-29.1684-3.6431-0.38770.690.44960.0486-2.95930.4695-29.1684QC'd by SIGMAInactive0-4.61374.0950.9877-26.8039-1.540 0 0 0 0 0 0 0-26.5033-0.4236-2.0019
Activator21.6899156.736741Partial curve; high efficacy-4.66371.64360.9965152.646-4.09072.10 0 0 0 0 0 0 0139.0219-7.688-5.9205-2.6984-6.44832.92063.305165.1579139.0219QC'd by SIGMAActivator21.6899162.56741Partial curve; high efficacy-4.66371.1110.9904149.6613-12.90572.10 0 0 0 0 0 0 0123.4829-22.2955-11.9211
Inhibitor68.5896112.34550Single point of activity-4.16374.95490.9828-132.1561-19.8107-30 0 0 0 0 0 0 0-111.2426-20.1826-20.8287-18.7981-28.0886-17.1914-20.5085-12.8968-111.2426QC'd by SIGMAInhibitor68.589686.73230Single point of activity-4.16374.44950.9873-113.865-27.1328-30 0 0 0 0 0 0 0-95.3644-28.9816-26.9911
Inactive0-7.66373.92950.7686-7.2282.540 0 0 0 0 0 0 0-11.02341.09824.1458-4.8418-4.8691-9.443-3.8914-6.5282-11.0234QC'd by SIGMAInactive0-4.16374.95490.651-27.8917-340 0 0 0 0 0 0 0-23.2431-6.656-9.2309
Inactive0-4.41371.3310.898714-3.05240 0 0 0 0 0 0 011.0873-2.5867-3.2326-5.0433-4.6999-1.27990.11610.26511.0873QC'd by SIGMAInactive0-4.36374.0450.886215-0.287740 0 0 0 0 0 0 014.36781.375-2.3231
Inactive0-6.16370.20.775424-16.551840 0 0 0 0 0 0 017.516-13.7932-1.0086-0.097-3.61628.21882.019310.451717.516QC'd by SIGMAInactive0-4.76371.37230.927516.5-1.30240 0 0 0 0 0 0 014.8217-2.0042-1.1245
Activator6.85978.349582Complete curve; high efficacy-5.16372.35310.993574.2594-4.091.10 0 0 0 0 0 0 074.1184-4.5486-4.6511-8.825-2.30471.465710.463767.365974.1184QC'd by SIGMAActivator10.8707114.427843Partial curve; high efficacy-4.96371.47810.9985115.03150.60372.10 0 0 0 0 0 0 0113.44331.03430.5738
Inactive0-6.51374.95490.5499-7.6782040 0 0 0 0 0 0 1-1.3248-6.98861.92394.42461.2121-9.7318-6.8313-5.9944-1.3248QC'd by LightBiologicalsInactive0004-8.6845-1.797-2.7987
Inactive0-5.41370.80.90046-18.099440 0 0 0 0 0 0 1-21.7232-17.1597-21.7495-14.3887-17.1525-11.21-8.4462.3181-21.7232QC'd by SIGMAInactive0-5.21372.09370.8981-0.2998-16.214240 0 0 0 0 0 0 1-31.9687-17.1088-15.6886
Activator7.6959120.525544Partial curve; high efficacy-5.11370.70.9928114.4923-6.03322.10 0 0 0 0 0 0 096.374-4.3635-4.0674-6.7463-2.631320.309836.671572.031796.374QC'd by SIGMAActivator21.6899154.602341Partial curve; high efficacy-4.66370.70.9681162.64828.04592.11 0 0 0 0 0 0 0124.921836.981711.0863
Inhibitor68.589653.68390Single point of activity-4.16374.95490.8843-56.1458-2.4619-30 0 0 0 0 0 0 0-46.1475-3.3066-1.056-2.431-2.1781-4.9409-11.84398.4719-46.1475QC'd by SIGMAInhibitor68.589653.39790Single point of activity-4.16373.990.8078-57.5482-4.1503-30 0 0 0 0 0 0 0-45.11221.3906-2.0624
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PGC756
Protocol: Tox21 Assay Protocol Summary:

The PGC/ERR cells were dispensed at 2,000 cells/5 ul/well in 1536-well white plates using a Multidrop dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 6 hours, 23 nL of compounds dissolved in DMSO, positive and negative controls or DMSO only was transferred to the assay plate by a pin tool. The plates were incubated at 37 C for 18 hours. 4 ul/well of One-Glo reagent was added into the assay plates using a Flying Reagent Dispenser. After 30 min incubation at room temperature, the luminescence intensity in the plates was measured using a ViewLux plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005899000 uM-Replicate_1Activity at 0.00118 uM-Replicate_1Activity at 0.00295 uM-Replicate_1Activity at 0.00590 uM-Replicate_1Activity at 0.015 uM-Replicate_1Activity at 0.029 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.369 uM-Replicate_1Activity at 0.737 uM-Replicate_1Activity at 1.843 uM-Replicate_1Activity at 3.687 uM-Replicate_1Activity at 9.217 uM-Replicate_1Activity at 18.43 uM-Replicate_1Activity at 46.08 uM-Replicate_1Activity at 92.17 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2Excluded_Points-Replicate_2Max_Response-Replicate_2Activity at 0.0005899000 uM-Replicate_2Activity at 0.00118 uM-Replicate_2Activity at 0.00295 uM-Replicate_2Activity at 0.00590 uM-Replicate_2Activity at 0.015 uM-Replicate_2
Inactive0-7.86374.95490.4691-10.890740 0 0 0 0 0 0 08.2951-3.5934-17.82563.728-3.3143-3.1544-3.41174.3528.2951QC'd by EnamineInactive0-5.91374.95490.48948.51.175740 0 0 0 0 0 0 08.48355.7-2.2368
Inactive0-7.21374.95490.40832.5-6.308740 0 0 0 0 0 0 1-10.1762-3.3308-8.1739-6.92184.266411.9083-0.5284-5.8356-10.1762QC'd by EnamineInactive0-7.21374.95490.3691-6.9367-1.540 0 0 0 0 0 0 0-5.5669-7.1362-0.1385
Inhibitor1.9331113.210487Complete curve; high efficacy-5.71374.95490.9846-123.2827-10.0723-1.10 0 0 0 0 0 0 0-117.206-10.7699-22.4888-12.4254-6.51180.6162-122.7414-125.2872-117.206QC'd by EnamineInhibitor1.9331120.518410Complete curve; high efficacy; poor fit-5.71374.95490.9442-119.760.7584-1.31 0 0 0 0 0 0 0-113.3163-116.2959-15.8547
Inactive0-8.81374.95490.6276-1.5-23.330940 0 0 0 0 0 0 0-6.9561-18.60914.2346-0.05635.7534-2.7207-6.6784-4.0458-6.9561QC'd by EnamineInactive0-4.91374.95490.67133-13.282940 0 0 0 0 0 0 1-8.9666-10.8624-14.0596
Inhibitor48.557734.128310Partial curve; partial efficacy; poor fit-4.31371.59360.9877-48.5369-14.4086-2.40 0 0 0 0 0 0 0-39.4219-12.8405-14.8776-15.1051-14.86-12.8749-15.8706-20.1132-39.4219QC'd by SIGMAInhibitor68.589642.307610Single point of activity-4.16373.990.6044-42.24050.0671-30 0 0 0 0 0 0 0-32.3397-15.868116.9894
Inactive0-7.96374.95490.741.5-10.355940 0 0 0 0 0 0 1-15.0169-9.9531-10.71334.5939-1.7304-1.45467.6602-0.5767-15.0169QC'd by SIGMAInactive0004-14.859-13.2163-9.3098
Inactive0-6.51374.95490.59899-2.513340 0 0 0 0 0 0 011.69730.78462.1119-10.0111-3.685212.17340.718111.618411.6973QC'd by SIGMAInactive040 0 0 0 0 0 0 016.3373-14.8015-9.7381
Inhibitor68.589632.190510Partial curve; partial efficacy; poor fit-4.16374.95490.9333-32.19050-2.40 0 0 0 0 0 0 0-25.9921-0.75610.9798-0.51641.0571-2.5971-2.18895.2808-25.9921QC'd by SIGMAInhibitor54.482738.551110Single point of activity-4.26373.67720.7506-35.47323.0779-30 0 0 0 0 0 0 0-30.5241-3.270317.9183
Activator7.695932.09880Complete curve; partial efficacy; poor fit-5.11371.17050.89385.5-26.59881.40 0 0 0 0 0 0 03.0626-32.5823-21.1084-29.0917-26.3315-18.7973-20.4148-1.32993.0626QC'd by SIGMAInactive0-7.46374.50450.4143-10.33733.540 0 0 0 0 0 0 17.47462.66914.4156
Inactive0-8.81374.44950.581.039522.540 0 0 0 0 0 0 119.8217.5365-0.7335-0.826912.2606-2.48681.3946-4.133719.82QC'd by SIGMAInactive00044.4393-3.40321.9365
Activator9.688587.44380Partial curve; high efficacy-5.01371.1110.9835.4518-51.99212.10 0 0 0 0 0 0 031.4522-53.6971-45.0647-53.1956-58.3066-41.7857-30.32154.685831.4522QC'd by SIGMAActivator24.3365131.06770Partial curve; high efficacy-4.61371.13410.970482.8838-48.18392.10 0 0 0 0 0 0 060.7185-41.9229-50.2592
Inhibitor68.5896102.999410Single point of activity-4.16374.95490.9126-112.465-9.4656-30 0 0 0 0 0 0 0-93.2546-12.8632-27.0848-7.3454-8.8555-9.7568-7.97886.4016-93.2546QC'd by SIGMAInhibitor68.589685.608410Single point of activity-4.16374.95490.944-101.5037-15.8953-30 0 0 0 0 0 0 0-85.4409-16.1487-18.1915
Inhibitor21.689934.032910Partial curve; partial efficacy; poor fit-4.66371.47870.8531-36.5329-2.5-2.40 0 1 0 0 0 0 0-32.94412.3801-9.142323.5287-7.26264.059-6.3199-16.9462-32.9441QC'd by SIGMAInactive0-4.76373.92950.9033-24.5486040 0 0 0 0 0 0 0-24.62381.1616-5.4271
Inactive0-8.36370.60.5758-5.19734.497140 0 0 0 0 0 0 0-1.492426.08197.16867.27432.4662-0.9291-23.91225.1445-1.4924QC'd by SIGMAInactive0-6.06372.40640.6203-9.38677.540 0 1 0 0 0 0 1-0.299213.05514.9918
Inactive0-8.81374.95490.7618-4.635640 0 0 0 0 0 0 10.89323.8508-8.0292-4.7013-4.9681-1.7031-4.6863-4.9470.8932QC'd by SIGMAInactive0-6.16373.92950.60363-4.918140 0 0 0 0 0 0 1-8.3052-1.6572-3.0816
Activator9.6885153.03170Complete curve; high efficacy-5.01372.95230.9881152.6925-0.33921.10 0 0 0 0 0 0 0154.2348-8.4111-10.58393.4205-1.171512.040612.3376130.2412154.2348QC'd by SIGMAActivator13.6854129.32160Complete curve; high efficacy-4.86374.95490.9964137.38078.0591.11 0 0 0 0 0 0 0137.932449.111113.295
Inactive0-4.91374.95490.444-12.5490.540 0 0 0 0 0 0 15.8614-0.0331-9.32676.6938-0.25312.49384.0461-11.29095.8614QC'd by LightBiologicalsInactive0004-2.7991-4.8479-7.8846
Activator24.336541.70840Single point of activity-4.61374.0950.931932.657-9.051430 0 0 0 0 0 0 032.0784-3.5663-7.3386-15.2356-4.8834-11.4699-12.65141.923932.0784QC'd by SIGMAActivator48.557746.25170Single point of activity-4.31374.95490.885537.4014-8.850230 0 0 0 0 0 0 035.5314-6.6661-5.471
Activator6.1131159.82730Complete curve; high efficacy-5.21372.53340.9773152.783-7.04431.10 0 0 0 0 0 0 0153.3966-25.2204-14.08523.3931-8.592911.330526.7308143.426153.3966QC'd by SIGMAActivator24.336560.25150Partial curve; high efficacy; poor fit-4.61374.0950.6456118.703558.45192.30 0 0 0 0 0 0 0117.761480.334882.544
Inhibitor1.722939.472922Partial curve; partial efficacy-5.76371.41630.986-34.97294.5-2.20 0 0 0 0 0 0 14.48376.73975.89010.58273.8988-4.4773-25.2126-33.31084.4837QC'd by SIGMAInhibitor6.85939.386121Partial curve; partial efficacy-5.16370.80.943-41.2694-1.8833-2.20 0 0 0 0 0 0 18.8427-1.1528-2.3725
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Danio rerio
External ID: CHEMBL4425011
Protocol: N/A
Comment: Journal: J Nat Prod
Year: 2019
Volume: 82
Issue: 3
First Page: 510
Last Page: 519
DOI: 10.1021/acs.jnatprod.8b00893

Target ChEMBL ID: CHEMBL613963
ChEMBL Target Name: Danio rerio
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Activity=52%
Activity=81%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:HL-60
External ID: CHEMBL1105632
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 2010
Volume: 53
Issue: 10
First Page: 3964
Last Page: 3972
DOI: 10.1021/jm901805m

Target ChEMBL ID: CHEMBL383
ChEMBL Target Name: HL-60
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
13.1IC50=13100nM
5.5IC50=5500nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:HL-60
External ID: CHEMBL1105631
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 2010
Volume: 53
Issue: 10
First Page: 3964
Last Page: 3972
DOI: 10.1021/jm901805m

Target ChEMBL ID: CHEMBL383
ChEMBL Target Name: HL-60
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
13.2IC50=13200nM
5.6IC50=5600nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK159
Protocol: Assay Protocol Summary:

The medium for SNB-19 cells is composed of RPMI 1640 (ATCC, Cat.# 30-2001), 10% fetal bovine serum (FBS) (GE healthcare Life Sciences, Cat.# SH30071.03), and 1% Pen/Strep (Gibco, Cat.# 15140-122). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 250 cells/well in 3ul medium for SNB-19 cells in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inactive0-6.57924.95490.3504-2.229914.585140 0 0 0 0 0 0 0 0 0 0-5.356915.474625.14691.32891.457930.092112.8619-9.5062-12.2483-4.443920.4415-5.3569QC'd by BIOMOL
Inactive00040.140559.29224.527917.63713.780410.6882-1.5038-3.37094.203930.3994-1.99860.1405QC'd by BIOMOL
Inactive0-8.32924.95490.7822-3.268722.540 0 0 0 0 0 0 0 0 0 0-5.221915.927728.3896-3.44590.9788-0.6642-4.0601-8.14096.6432-8.9739-5.0251-5.2219QC'd by BIOMOL
Inactive0-7.17923.06540.4254932.145740 0 0 0 0 0 0 0 0 0 135.30295.277541.434433.152350.303620.24367.33299.210316.67199.450714.423135.3029QC'd by BIOMOL
Inactive0-8.37924.95490.35830.9315.540 0 0 0 0 0 0 0 0 0 119.319111.410119.1762-0.614-5.8917-0.005821.4835-3.85571.8137-0.8127-2.822419.3191QC'd by BIOMOL
Activator26.3506106.31810Single point of activity-4.57924.95490.950195.6321-10.685930 0 0 0 0 0 0 0 0 0 089.5669-8.1996-4.634-16.5004-16.3027-20.3551-20.1104-2.4639-1.956-4.3704-4.164789.5669QC'd by BIOMOL
Inactive0-9.02924.95490.39864-15.151240 0 0 0 0 0 0 0 0 0 011.3272-9.70937.84233.37613.399312.5003-0.1871-0.4744-2.70083.131-0.583111.3272QC'd by BIOMOL
Inactive0-4.47920.80.6034-34.4978-440 0 0 0 0 0 0 0 0 0 0-27.0815-0.6401-2.5148-2.2817-11.00811.0964-8.2348-11.6629-9.9639-6.098-9.2602-27.0815QC'd by BIOMOL
Inactive0004-0.534621.15938.357233.008610.588322.210240.91430.450915.303915.248315.763-0.5346QC'd by BIOMOL
Inactive0-7.37924.95490.72140.194224.863440 0 0 0 0 0 0 0 0 0 04.066615.530928.052423.038933.3812-2.1843-9.34578.111511.7564-7.393-1.86714.0666QC'd by BIOMOL
Inactive0004-29.782-16.4018-13.9219-14.5268-17.1479-18.872416.6048-0.8381-12.8788-19.3078-27.9636-29.782QC'd by BIOMOL
Inactive0004-9.6121-3.3856-4.2081-0.1463-6.8307-5.50433.9502-1.1496-1.2765-3.5332-1.7407-9.6121QC'd by BIOMOL
Activator0.331733.60330Complete curve; partial efficacy; poor fit-6.47920.70.714330.0135-3.58981.40 0 0 0 0 0 0 0 0 0 022.2786-3.1933-2.4551-4.04170.021512.07325.324119.20397.398643.355928.542722.2786QC'd by BIOMOL
Inactive0004-9.58580.041-18.54712.7931-0.1637-0.4717-3.0273-11.8154-12.2288-9.8437-6.1918-9.5858QC'd by BIOMOL
Inactive00043.544242.3006-2.999222.3937.6161-4.116332.17070.342-5.177242.8575-0.91733.5442QC'd by BIOMOL
Inactive0-6.37924.95490.3244-0.6421040 0 0 1 0 0 0 0 0 0 15.11119.82912.00793.113638.3079-0.532125.7035-1.3518-3.035-0.42124.22735.1111QC'd by BIOMOL
Inactive0-6.87924.95490.39070.6238.540 0 0 0 0 0 0 0 0 0 17.33186.6121-0.51588.08089.177318.9883-0.89744.13632.4077-2.3975-0.54117.3318QC'd by BIOMOL
Inactive0-7.62922.25260.46726-9.673540 0 0 0 0 0 0 0 0 0 04.0434-5.2371-12.2279-11.2597-1.22923.2718-0.865126.0229-0.0171-0.60298.95184.0434QC'd by BIOMOL
Inactive0004-0.5003-6.954428.7797-7.1636-6.6411.8449-16.4193-9.0529-12.5437-4.3363-10.7171-0.5003QC'd by BIOMOL
Inactive00049.9428-15.654318.1375-12.36-2.562816.0422-19.5863-8.3403-1.4148-7.26780.13079.9428QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK097
Protocol: Assay Protocol Summary:

The medium for hNPCs consists of DMEM/F12, N2 supplement (ThermoFisher, Cat.# 17502048), NEAA (ThermoFisher, Cat. # 11140050), 2 ug/ml heparin, 2 uM cyclopamine, and B27 (ThermoFisher, Cat. # 17504044). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 350 cells/well in 3 ul medium for hNPCs in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inhibitor1.177177.955893Complete curve; high efficacy-5.92924.44950.9941-184.5509-6.595-1.10 0 0 0 0 0 0 0 0 0 0-185.5575-4.6679-6.07642.0148-8.4168-11.0338-21.5021-2.901-155.7275-182.4713-186.415-185.5575QC'd by Toronto Research
Inhibitor1.1471185.207193Complete curve; high efficacy-5.94041.210.97-180.93524.2719-1.10 0 0 0 0 0 0 0 0 0 0-177.4789-1.8992-5.87563.952936.1181-2.14-22.9111-15.9848-71.7614-129.8809-162.4978-177.4789QC'd by Selleck
Inhibitor1.6626168.127491Complete curve; high efficacy-5.77923.1320.9837-169.0446-0.9171-1.10 0 0 0 0 0 0 0 0 0 0-168.1209-22.0426-2.082-5.32045.54071.319-1.450114.7212-89.7232-163.7665-168.7071-168.1209QC'd by Toronto Research
Inhibitor1.6626180.916791Complete curve; high efficacy-5.77923.06540.9946-179.00781.9089-1.11 0 0 0 0 0 0 0 0 0 0-184.164424.6062-0.25336.7266-4.25895.2703-6.96233.8251-93.9542-164.0777-181.1503-184.1644QC'd by Microsource
Inhibitor2.5119207.7491Complete curve; high efficacy-5.61.28761-191.831715.9083-1.10 0 0 0-186.97050.1857-67.9483-158.9713-186.9705QC'd by SIGMA
Inhibitor2.6351194.953890Complete curve; high efficacy-5.57923.1320.9719-181.527713.4261-1.10 0 0 0 0 0 0 0 0 0 0-182.0412-10.1591-4.327141.72652.806130.91214.291818.2215-27.3816-157.9177-180.8355-182.0412QC'd by Microsource
Inhibitor2.6351187.857190Complete curve; high efficacy-5.57921.96730.9892-184.8163.0411-1.10 0 0 0 0 0 0 0 0 0 0-185.5582-11.96489.2141-3.2711.099417.1828-3.5684-6.2672-52.0668-151.5101-173.32-185.5582QC'd by NCGCChem
Inhibitor1.049135.304590Complete curve; high efficacy-5.97921.210.9819-141.7236-6.4191-1.10 0 0 0 0 0 0 0 0 0 0-147.6287-12.4793-9.977-7.7012-7.9502-2.9377-8.1662-64.6761-88.8563-120.3966-133.137-147.6287QC'd by SantaCruz Bio
Inhibitor2.8184216.384690Complete curve; high efficacy-5.551.69240.9997-186.295930.0887-1.10 0 0 0-182.643124.865-42.6314-161.1067-182.6431QC'd by SIGMA
Inhibitor2.3485163.71489Complete curve; high efficacy-5.62922.25260.9797-163.7140-1.10 0 0 0 0 0 0 0 0 0 0-160.5039-3.8215-6.7268-7.215321.45223.6974-17.7659-0.4266-46.4433-147.1554-160.0245-160.5039QC'd by Chemscene
Inhibitor2.6351163.489589Complete curve; high efficacy-5.57922.90230.9893-160.83712.6524-1.10 0 0 0 0 0 0 0 0 0 0-164.4551-6.438912.37438.80558.37418.3794-11.7519-4.8192-29.5494-138.8745-157.2471-164.4551QC'd by NCGCChem
Inhibitor4.6859191.442587Complete curve; high efficacy-5.32923.1320.9826-168.314323.1281-1.10 0 0 0 0 0 0 0 0 0 0-166.876718.290114.40469.045234.10942.835721.691110.381325.2215-83.459-167.42-166.8767QC'd by Selleck
Inhibitor4.6859162.961287Complete curve; high efficacy-5.32922.24810.9856-169.2903-6.3291-1.10 0 0 0 0 0 0 0 0 0 0-177.4531-11.75413.3773-4.3533-18.2902-11.7259-2.3524-8.7407-13.4287-99.7645-147.5191-177.4531QC'd by XcessBio
Inhibitor3.7221126.784186Complete curve; high efficacy-5.42921.46410.957-135.7206-8.9365-1.10 0 0 0 0 0 0 0 0 0 0-142.2647-0.6771-6.2358-11.2121-16.6768-27.3011-0.3514-8.3109-35.4059-95.2772-106.0275-142.2647QC'd by Toronto Research
Inhibitor9.3495220.010985Complete curve; high efficacy-5.02922.33320.9927-186.75533.2559-1.10 0 0 0 0 0 0 0 0 0 0-173.508727.166126.046340.016235.561841.045434.729824.282529.7949-6.87-142.7818-173.5087QC'd by Selleck
Inhibitor10130.300384Complete curve; high efficacy-52.78680.9985-148.0456-17.7453-1.10 0 0 0-146.7041-67.4842-127.8599-147.7501-146.7041QC'd by SIGMA
Inhibitor10145.260384Complete curve; high efficacy-51.78850.9997-161.3387-16.0784-1.10 0 0 0-152.7828-41.646-82.1916-129.7354-152.7828QC'd by GVK
Inhibitor3.162382.146984Complete curve; high efficacy-5.52.18761-81.06551.0814-1.10 0 0 0-79.882-22.1789-55.8956-75.2948-79.882QC'd by SIGMA
Inhibitor10127.897283Complete curve; high efficacy-51.62590.9999-122.48425.4131-1.10 0 0 0-119.3803-48.5016-88.2414-110.9773-119.3803QC'd by SIGMA
Inhibitor9.349566.453582Complete curve; high efficacy-5.02922.25260.9036-65.87540.5781-1.10 0 0 0 0 0 1 0 0 0 0-62.9964-8.14449.52244.22022.849611.2227-15.585328.5669-1.4504-13.5243-50.6989-62.9964QC'd by Toronto Research
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Southern Research Institute 靶标:CFTR
External ID: CF Folding
Protocol: A high throughput 384-well microplate based fluorescence assay was developed using HeLa cells engineered to express F508del-CFTR. Cells were maintained in cell culture media (High Glucose DMEM (Gibco) supplemented w/ 10% FBS (Gibco)). For the assay, cells were trypsinized (0.25% Trypsin-EDTA solution (Gibco)) and resuspended in assay media (cell culture media + 1% Pen/Strep (Gibco)) at a density of 320,000 cells per ml. Cells were dispensed to the assay plates (Corning 3712) in 25 ul using a Wellmate (Matrix/Thermo). Plates were incubated overnight at 37C, 5% CO2 and high humidity. The next day, compounds were prepared by making a dilution in assay media to a concentration of either 150 uM or 60 ug/ml (6x) depending on the library being screened. Then 5 ul of the diluted compound was transferred to the assay plate containing the cells. Assay plates were incubated for 24 hours 37C, 5% CO2 and high humidity. Following incubation with the compounds, relative cell number was determined by adding 3 ul of alamarBlue (TREK Diagnostics) and incubating the plates at 37C, 5% CO2 and high humidity, until cell control values reached ~4 million, as measured with a fluorescent intensity protocol on an Envision multimode plate reader (Perkin Elmer) (excitation 535 nm, emission 595 nm wavelengths) . Following the alamarBlue read, the media was removed and the cells were fixed with the addition of 13 ul of 4% paraformaldehyde in PBS (pH 7.4) and incubated for 10 minutes at room temperature. Plates were washed twice with PBS to remove the fixative. Cells were permeabilized with the addition of blocking solution (PBS, 0. 1% Triton X-100, 10 mg/ml BSA) and incubated at room temperature for 30 minutes. The blocking solution was removed and the primary antibody mixture was added in 13ul (Antibodies UNC570 and UNC596; CFF Therapeutics, Inc., Bedford, MA) at a 1/5000 dilution of each antibody in blocking solution. Plates were then incubated over night at 4oC. Primary antibody was removed by washing three times with 50 ul of wash solution (PBS, 0.1% Triton X-100) with at least 5 minutes between wash cycles. Secondary antibody (Alexa 488 anti-mouse IgG Invitrogen) was then added in a volume of 13 ul (1/1000 dilution in blocking solution) and incubated for two hours at room temperature in the dark. To remove excess secondary antibody, plates were washed three times with 50 ul of wash solution and one time with 50 ul of PBS. Plates were read from the bottom using a fluorescent intensity protocol on an Envision multimode plate reader (485 nm excitation and 535 nm emission).
To minimize the disruption of the cell monolayer during the numerous washes, the following process was used. The removal of media or other reagents for the wells of the microtiter plate was done using a Biomek FX (Beckman, Fullerton CA) with a 384 tip multichannel head. Aspiration was done at a slow rate following the liquid level with the tip positioned in the top right corner of the well. All solution additions, starting with the fixative, were done with a Matrix Wellmate. Again to avoid disturbing the cell monolayer, the plate offset was adjusted so that the liquid dispensed to the left wall of the well rather than directly on the cell monolayer.
For the screen, approximately ten thousand compounds from a mix of FDA and diverse libraries (MicroSource Pharmacon-1600 (FDA), Enzo (FDA), Selleck (FDA) and Enamine) were tested at a final concentration 25 uM (Enzo, Selleck & MS Pharmakon) or 10 ug/ml (Enamine 30K diversity set). The proteasome inhibitor ALLN was used as the positive control (50 uM) and 100 uM Hyamine was used as a viability control on all microtiter plates. All wells including the cell controls contained 0.5% DMSO. In-plate controls were used to normalize the data and results were reported as fold increase above the cell control and normalized to relative cell number derived from the alamarBlue data.
Ninety six compounds identified in the single dose screen were evaluated further in dose response. Compound high dose was twice the screening concentration and a ten point series of two fold dilutions were done for each compound. DMSO concentration was 1% for in all wells. Compounds were evaluated in both the immunostain assay and in the cell viability assay.

Data Analysis: Thirty two control wells containing cells only, 24 wells containing Hyamine and 8 wells containing ALLN were included on each assay plate and used to calculate Z' value for each plate and to normalize the data on a per plate basis. Data were analyzed using the IDBS Activity Base software. Results were expressed as Fold Increase (FI) for the immunostain assay and cell viability (V) for the alamarBlue assay. Final data was reported as Normalized fold increase (NFI). Data was analyzed as follows FI=DataValue/Median cell control, V= (DataValue-median Hyamine control)/(median cell control -median Hyamine control) and NFI=FI/V.

For the immunostain dose response assay, IC50 values were calculated for active compounds by plotting the FI for each concentration, and using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0. Similarly, EC50 values were calculated for the cell viability dose response assay, plotting the % Viability at each concentration and also using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0 and the maximum limit set at 100.

Outcome- From the primary screen, compounds selected as Active were those that met one of the following two criteria: (1) Fold Induction >/= 1.5, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/= 1.5; or (2) Fold Induction >/= 1, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/=1.75. While 101 compounds met this criteria, 96 were ultimately selected for confirmatory screening. For the dose response screen, compounds were labeled as "Active" if they showed at least 8 fold increase over the ALLN control at any concentration.
Comment: Possible Artifacts: Possible artifacts in this assay include, but are not limited to, compounds that are fluorescent, absorb at the excitation or emission wavelengths, or non-specifically upregulate protein expression
IC50 ModifierIC50IC50 Fit Hill SlopeIC50 Fit NormChi2IC50 Fit StDevMax Fold IncreaseConc @Max Fold IncreaseEC50 ModifierEC50EC50 Fit Hill SlopeEC50 Fit NormChi2EC50 Fit StDevFold Increase @50 uM Rep1Fold Increase @25 uM Rep1Fold Increase @12.5 uM Rep1Fold Increase @6.25 uM Rep1Fold Increase @3.13 uM Rep1Fold Increase @1.56 uM Rep1Fold Increase @0.78 uM Rep1Fold Increase @0.39 uM Rep1Fold Increase @0.2 uM Rep1Fold Increase @0.09 uM Rep1Fold Increase @20 ug/ml Rep1Fold Increase @10 ug/ml Rep1Fold Increase @5 ug/ml Rep1Fold Increase @2.5 ug/ml Rep1Fold Increase @1.25 ug/ml Rep1Fold Increase @0.63 ug/ml Rep1Fold Increase @0.31 ug/ml Rep1Fold Increase @0.156 ug/ml Rep1Fold Increase @0.078 ug/ml Rep1Fold Increase @0.039 ug/ml Rep1Fold Increase @50 uM Rep2Fold Increase @25 uM Rep2Fold Increase @12.5 uM Rep2Fold Increase @6.25 uM Rep2Fold Increase @3.13 uM Rep2Fold Increase @1.56 uM Rep2Fold Increase @0.78 uM Rep2Fold Increase @0.39 uM Rep2Fold Increase @0.2 uM Rep2Fold Increase @0.09 uM Rep2Fold Increase @20 ug/ml Rep2Fold Increase @10 ug/ml Rep2Fold Increase @5 ug/ml Rep2Fold Increase @2.5 ug/ml Rep2Fold Increase @1.25 ug/ml Rep2Fold Increase @0.63 ug/ml Rep2Fold Increase @0.31 ug/ml Rep2Fold Increase @0.156 ug/ml Rep2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:HL-60
External ID: CHEMBL1105633
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 2010
Volume: 53
Issue: 10
First Page: 3964
Last Page: 3972
DOI: 10.1021/jm901805m

Target ChEMBL ID: CHEMBL383
ChEMBL Target Name: HL-60
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard Value
Ratio IC50>1000
Ratio IC50=0.26
Ratio IC50=3.74
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Tubulin beta-2B chain
External ID: CHEMBL819687
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 2000
Volume: 43
Issue: 12
First Page: 2419
Last Page: 2429
DOI: 10.1021/jm0001119

Target ChEMBL ID: CHEMBL2094134
ChEMBL Target Name: Tubulin
ChEMBL Target Type: PROTEIN FAMILY - Target is a group of closely related proteins
Relationship Type: D - Direct protein target assigned
Confidence: Multiple direct protein targets may be assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=60%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Southern Research Institute 靶标:HIV-1 Vif
External ID: HIV1-VIF_MS
Protocol: The assay protocol for screening and testing compounds included plating a mixture of GST-Vif "donor" protein and bio-A3G "acceptor" peptide with test compounds in white, non-binding surface 1536-well plates. LANCE reagents were purchased from PerkinElmer. Briefly, 15nM GST-Vif protein was added to the assay plate containing test compounds. Following a 30 minute incubation, 500 nM bio-A3G peptide was added. Following another 30 minute incubation, 2 nM Eu-labeled anti-GST and 50 nM streptavidin-Ulight detection reagents were added to the assay plate and incubated for 1 hour. After the final incubation, TR-FRET signals were measured using an Envision microplate reader with excitation at 340 nm and emission at 615 and 665 nm. The emission at 615 nm from Eu-labeled anti-GST induces emission at 665 nm from Ulight conjugated to streptavidin when the two molecules are in close proximity, resulting in a FRET signal. GST-Vif binding to the bio-A3G peptide produced a significant increase in the FRET signal over background levels measured in the presence of GST.

To evaluate the screening results each plate included negative and positive controls. Negative control wells included all assay components in the absence of an inhibitor and positive control wells included all assay components with GST-Vif 1-94 protein replaced by GST protein. Percent inhibition was determined as: 100*((Test Compound Signal - Median Negative Control Signal)/(Median Positive Control Signal - Median Negative Control Signal)).
Comment: In the Dose Response, compounds that showed >30% inhibition for at least one concentration were considered potentially active, however some compounds were tested in dose response on more than one occasion. If conflicting results were observed, the compound was deemed "inconclusive". Only compounds that consistently showed activity across all test dates were labeled "Active". Any compounds in the primary screen active range that were not available for testing in dose response were labeled "Inconslusive".
The following tiered system has been implemented at Southern Research Institute for use with the PubChem Score. Compounds in the primary screen are scored on a scale of 0-40 based on inhibitory activity where a score of 40 corresponds to 100% inhibition. In the confirmatory dose response screen, active compounds were scored on a scale of 41-80 based on the average IC50 result, inconclusive compounds were given the lowest confirmatory score of 41, and compounds that were tested and did not confirm as actives were given the score 0.
Average IC50 ModifierAverage IC50IC50 Modifier Rep1IC50 Rep 1IC50 Modifier Rep2IC50 Rep2IC50 Modifier Rep3IC50 Rep3StDev IC50 Rep1IC50 Hill Slope Rep1IC50 NormChi2 Rep1StDev IC50 Rep2IC50 Hill Slope Rep2IC50 NormChi2 Rep2StDev IC50 Rep3IC50 Hill Slope Rep3IC50 NormChi2 Rep3Pct Inhibition @ 100 uM Rep1Pct Inhibition @ 50 uM Rep1Pct Inhibition @ 25 uM Rep1Pct Inhibition @ 12.5 uM Rep1Pct Inhibition @ 6.25 uM Rep1Pct Inhibition @ 3.125 uM Rep1Pct Inhibition @ 1.563 uM Rep1Pct Inhibition @ 0.781 uM Rep1Pct Inhibition @ 0.391 uM Rep1Pct Inhibition @ 0.195 uM Rep1Pct Inhibition @ 100 uM Rep2Pct Inhibition @ 50 uM Rep2Pct Inhibition @ 25 uM Rep2Pct Inhibition @ 12.5 uM Rep2Pct Inhibition @ 6.25 uM Rep2Pct Inhibition @ 3.125 uM Rep2Pct Inhibition @ 1.563 uM Rep2Pct Inhibition @ 0.781 uM Rep2Pct Inhibition @ 0.391 uM Rep2Pct Inhibition @ 0.195 uM Rep2Pct Inhibition @ 100 uM Rep3Pct Inhibition @ 50 uM Rep3Pct Inhibition @ 25 uM Rep3Pct Inhibition @ 12.5 uM Rep3Pct Inhibition @ 6.25 uM Rep3Pct Inhibition @ 3.125 uM Rep3Pct Inhibition @ 1.563 uM Rep3Pct Inhibition @ 0.781 uM Rep3Pct Inhibition @ 0.391 uM Rep3Pct Inhibition @ 0.195 uM Rep3Max Inhibition Rep1Conc @ Max Inhibition Rep1Max Inhibition Rep2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Tubulin beta-2B chain
External ID: CHEMBL819686
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 2000
Volume: 43
Issue: 12
First Page: 2419
Last Page: 2429
DOI: 10.1021/jm0001119

Target ChEMBL ID: CHEMBL2094134
ChEMBL Target Name: Tubulin
ChEMBL Target Type: PROTEIN FAMILY - Target is a group of closely related proteins
Relationship Type: D - Direct protein target assigned
Confidence: Multiple direct protein targets may be assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=19%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4513082
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=0.24%
Inhibition=4.58%
Inhibition=-0.3%
Inhibition=-0.3%
Inhibition=-0.04%
Inhibition=-0.04%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=0.03%
Inhibition=0%
Inhibition=0.03%
Inhibition=0%
Inhibition=-0.27%
Inhibition=-0.27%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=14.41%
Inhibition=0.39%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Panel (Carcinoma cell lines)
External ID: CHEMBL694215
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 1997
Volume: 40
Issue: 15
First Page: 2323
Last Page: 2334
DOI: 10.1021/jm9700833

Target ChEMBL ID: CHEMBL612423
ChEMBL Target Name: Panel (Carcinoma cell lines)
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.13GI50=130nM
9.8GI50=9800nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Panel (Carcinoma cell lines)
External ID: CHEMBL694216
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: J. Med. Chem.
Year: 1995
Volume: 38
Issue: 12
First Page: 2041
Last Page: 2049
DOI: 10.1021/jm00012a003

Target ChEMBL ID: CHEMBL612423
ChEMBL Target Name: Panel (Carcinoma cell lines)
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
10GI50=10000nM
5.5GI50=5500nM
0.14GI50=140nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Tubulin beta-2B chain
External ID: CHEMBL819146
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1997
Volume: 40
Issue: 15
First Page: 2323
Last Page: 2334
DOI: 10.1021/jm9700833

Target ChEMBL ID: CHEMBL3394
ChEMBL Target Name: Tubulin beta chain
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=19%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:MDA-MB-435
External ID: CHEMBL1046466
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg. Med. Chem.
Year: 2009
Volume: 17
Issue: 20
First Page: 7344
Last Page: 7352
DOI: 10.1016/j.bmc.2009.08.038

Target ChEMBL ID: CHEMBL614697
ChEMBL Target Name: MDA-MB-435
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.58IC50=580nM
95.31IC50=95310nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:15218 靶标:N/A
External ID: ES_Opera
Protocol: To perform high content microscopy screening, HeLa cells with stable expression of F508del-CFTR were cultured in 96-well PE ViewPlates (Perkin Elmer, Waltham, MA) for one day prior to well by well addition of two thousand known bioactive compounds from the NIH Roadmap Molecular Libraries Small Molecule Repository. Ten mM DMSO stocks of compounds were diluted 500-fold in growth medium, then added in equal volume to assay plates to yield a final screening concentration of 10 M.
After a 24h treatment period, cells were fixed, permeabilized, and labeled with 3G11 antibody, which recognizes intracellular CFTR epitopes in NBD1, then visualized with AlexaFluor488 anti-mouse conjugate and DRAQ5 fluorescent DNA label (Axxora, Farmingdale, NY). Nine microscopic fields per sample well were then imaged using the Evotec Operatrade mark QEHS automated confocal microscope equipped with a 20x magnification Olympus objective lens (Perkin Elmer). Automated analysis of the resulting images was performed using Acapellatrade mark (Perkin Elmer) software as follows. High contrast labeling of cellular nuclei by DRAQ5 enabled rapid image segmentation by intensity threshold. Corresponding cytoplasm and cell margins associated with each nucleus were subsequently defined by image threshold of lower contrast cytoplasmic / RNA staining of DRAQ5. Further segmentation of images into regions of interest for analysis included plasma membrane (a 2 pixel wide region corresponding to cell margin) and perinuclear region (a 5 pixel wide region encircling the outside of the nuclear mask). Three criteria were used to track expression and subcellular localization of: 1) F508del-CFTR signal in the region of interest, designated as the plasma membrane (PM); 2) F508del-CFTR signal in the perinuclear region of the cell, as a proxy for the ER; and 3) fluorescence signal across the entire cell (Total) to monitor total F508del-CFTR protein. Each measurement was expressed as the mean fluorescent intensity for all cells imaged in 9 microscopic fields per sample.
Comment:
PM_IntensityTotal_IntensityTested_Concentration
808610
788810
11013410
727810
909210
9610210
909610
9910610
717710
869010
949410
838810
929610
929210
858510
9911410
909410
728010
889110
939710
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Tubulin beta-2B chain
External ID: CHEMBL817200
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1995
Volume: 38
Issue: 12
First Page: 2041
Last Page: 2049
DOI: 10.1021/jm00012a003

Target ChEMBL ID: CHEMBL3394
ChEMBL Target Name: Tubulin beta chain
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=38%
Inhibition=21%
Inhibition=32%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Burnham Center for Chemical Genomics 靶标:HNF4 Alpha
External ID: BHood-p-21Jun2013-01
Protocol: This assay is to identify inhibitors of HNF4 alpha protein binding to DNA
##

A. Materials:##
Description#Company#Cat #
1M TRIS #BioRad#161-0719
DTT#RPI#D11000
Glycerol#Amersco #0854-1L
NaCL#Fisher Bioreagents#BP358-212
Tween 20#Sigma#P1379
HNF4 Protein #Assay Provider#
FITC-DNA#Assay Provider#
1536 well black high base plate#Aurora#00019120BX
##
B. Plate Map:##
Positive control in columns 1 and 2 is DNA and 70nM Protein##
Negative control in columns 3 and 4, Protein at 650nM and DNA, DMSO##
Test compound in columns 5 - 48, Protein at 70nM + DNA + test compound

C. Procedures:##########
Step#Description#########
1#Transfer test compounds to columns 5-48, DMSO to columns 1-4 using ECHO 555.#########
2#Set up Envision as as described in G. Instrument setting.#########
3#Prepare assay buffer.#########
4#Dispense undiluted HNF4 protein solution at into col 3-4 and 140nM HNF4 protein into columns 1,2, and 5-48. #########
5#Dispense 3uL/well of FITC-DNA (FAC = 5nM) using BioRAPTR#########
6#Spin down plates on Eppendorf centrifuge 5810 at 1000 rpm for 1 minute.#########
7#Incubate plates at RT for 1 hour.#########
8#Read using FP protocol on Envision#########
##########
D. Assay Conditions:##########
Reagent##Final Conc.#Unit#######
1#Tris pH7.4#0.02#M#######
2#NaCl#0.05#M#######
3#DTT#0.01#M#######
4#Glycerol#10#%#######
5#Protein#650 for EC100 and 70nM for EC20#uM#######
6#DNA#5#nM#######
*#6uL reaction volume#########
*#60 min reaction at room temp#########
*#10uM test compound#########
*#0.5% DMSO
Comment:
%Activity_Corrected at 10 uMValue at 10 uMMean HighSTD Deviation HighMean LowSTD Deviation Low
-6.39105.0999985116.057.38199.696.53
-0.54109.8000031116.057.38199.696.53
-0.14111.9000015116.057.38199.696.53
3.17114.4000015116.057.38199.696.53
0.67110.0999985116.057.38199.696.53
-1.92108.3000031116.057.38199.696.53
-1.35108.0999985116.057.38199.696.53
1.56110.5999985116.057.38199.696.53
1.88112.1999969116.057.38199.696.53
1.69111.5999985116.057.38199.696.53
-0.73109.9000015116.057.38199.696.53
-0.36111.1999969116.057.38199.696.53
9.41119.5999985116.057.38199.696.53
-0.85109.3000031116.057.38199.696.53
-0.03110.0999985116.057.38199.696.53
2.36112116.057.38199.696.53
3.01113.1999969116.057.38199.696.53
-0.42109.0999985116.057.38199.696.53
-1.98107.5999985116.057.38199.696.53
0.83108.9000015116.057.38199.696.53
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Liver microsomes
External ID: CHEMBL1046473
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem.
Year: 2009
Volume: 17
Issue: 20
First Page: 7344
Last Page: 7352
DOI: 10.1016/j.bmc.2009.08.038

Target ChEMBL ID: CHEMBL613373
ChEMBL Target Name: Liver microsomes
ChEMBL Target Type: SUBCELLULAR - Target is a subcellular fraction
Relationship Type: S - Subcellular target assigned
Confidence: Target assigned is subcellular fraction
Standard TypeStandard RelationStandard ValueStandard Units
Stability=9.4%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Liver microsomes
External ID: CHEMBL1046471
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem.
Year: 2009
Volume: 17
Issue: 20
First Page: 7344
Last Page: 7352
DOI: 10.1016/j.bmc.2009.08.038

Target ChEMBL ID: CHEMBL613373
ChEMBL Target Name: Liver microsomes
ChEMBL Target Type: SUBCELLULAR - Target is a subcellular fraction
Relationship Type: S - Subcellular target assigned
Confidence: Target assigned is subcellular fraction
Standard TypeStandard RelationStandard ValueStandard Units
Stability=58%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Liver microsomes
External ID: CHEMBL1046472
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem.
Year: 2009
Volume: 17
Issue: 20
First Page: 7344
Last Page: 7352
DOI: 10.1016/j.bmc.2009.08.038

Target ChEMBL ID: CHEMBL613373
ChEMBL Target Name: Liver microsomes
ChEMBL Target Type: SUBCELLULAR - Target is a subcellular fraction
Relationship Type: S - Subcellular target assigned
Confidence: Target assigned is subcellular fraction
Standard TypeStandard RelationStandard ValueStandard Units
Stability=29%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:HUVEC
External ID: CHEMBL1046469
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Bioorg. Med. Chem.
Year: 2009
Volume: 17
Issue: 20
First Page: 7344
Last Page: 7352
DOI: 10.1016/j.bmc.2009.08.038

Target ChEMBL ID: CHEMBL613979
ChEMBL Target Name: HUVEC
ChEMBL Target Type: CELL-LINE - Target is a specific cell-line
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
0.26IC50=260nM
40.79IC50=40790nM